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RIASSUNTO
 
Background. La sclerosi sistemica (SSc) è una complessa patologia caratterizzata da una
eccessiva produzione di tessuto connettivo, una vasculopatia del microcircolo e disturbi
dell'autoimmunità.  L'ipertensione  arteriosa  polmonare  (IAP)  rappresenta  una  delle
complicanze più severe di questa patologia, gravata da una prognosi piuttosto infausta. La
diagnosi, data l’aspecificità dei sintomi, viene solitamente posta in uno stadio avanzato
della malattia, quando l’interessamento del letto vascolare polmonare è già severo. Proprio
per questo è fondamentale lo sviluppo di adeguate metodiche di screening per individuare
la  patologia  in  uno  stadio  precoce,  che  potrebbe  permettere  l'instaurazione  di  una
appropriata terapia e  migliorare la prognosi. 
Scopo dello studio. Valutare il comportamento della pressione arteriosa sistolica polmonare
in  un  gruppo  di  pazienti  affetti  da  SSc,  asintomatici  o  paucisintomatici,  sottoposti  ad
ecocardiografia da sforzo. I pazienti sono stati poi seguiti con un follow-up a medio-lungo
ripetendo un ecocardiogramma di base per valutare l'eventuale sviluppo di ipertensione
polmonare,  definendo  così  il  valore  predittivo  dell'ecocardiografia  da  sforzo
nell'identificare precocemente l'ipertensione polmonare. 
Materiali  e  Metodi. 40  pazienti  affetti  da  SSc  (33  femmine  e  7  maschi),  in  classe
funzionale NYHA I e II, e con normali valori di pressione arteriosa polmonare sistolica
(PAPs) a riposo sono stati sottoposti ad ecocardiogramma da sforzo. Sono stati valutati i
valori di PAPs a riposo e da sforzo, mediante la misurazione del jet di rigurgito tricuspidale
considerando patologica una PAPs da sforzo ≥ 48 mmHg. Sono stati  analizzati  inoltre
alcuni parametri emodinamici basali e da sforzo, le caratteristiche cliniche dei pazienti e
della patologia reumatologica di base, oltre che i valori di BNP basali e dopo sforzo. E'
stato eseguito un follow-up a medio-lungo termine (5,1 ± 0,4 anni) sottoponendo i pazienti
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ad una valutazione clinica e ad un ecocardiogramma di base per valutare lo sviluppo di
ipertensione polmonare. 
Risultati.  I valori di PAPs a riposo sono stati di 26,5±4,6 mmHg, raggiungendo valori di
45,1±14,2  mmHg  durante  esercizio  (p  0,00),  con  un  incremento  medio  di  18,7±11,9
mmHg. In 25 (62,5%) pazienti la PAPs da sforzo è risultata normale (Gruppo A), mentre in
15 pazienti (37,5%), tutti di sesso femminile, abbiamo riscontrato un’alterata vasoreattività
polmonare da sforzo (Gruppo B).  I  due gruppi  differivano significativamente sia  per  i
valori di PAPs a riposo (p 0,007) che da sforzo (p 0,00) ma anche per i valori di BNP da
sforzo e la variazione del BNP con l’esercizio (rispettivamente p 0,02 e p 0,001). Dei 40
pazienti iniziali,  2 sono deceduti per cause extracardiache e 2 pazienti sono stati persi;
abbiamo pertanto valutato 36 pazienti al follow-up di  5,1 ± 0,4 anni. La PAPs media a
riposo è risultata di 29,67 ± 7,4 mmHg. 5 pazienti, tutti appartenenti al gruppo B, hanno
presentato valori di PAPs a riposo patologici.  Tra questi, in 3 pazienti i  valori di PAPs
erano suggestivi per la diagnosi di possibile IAP (PAPs >37 mmHg), in 2 erano invece
indicativi  di  probabile  IAP (PAPs >50 mmHg).  Nessuno dei  pazienti  del  gruppo A ha
invece presentato nel follow-up valori di PAPs patologici. 
Conclusioni. La  prevalenza  di  alterata  vasoreattività  polmonare  indotta  dall'esercizio,
valutata tramite l'ecocardiografia da sforzo, è elevata nei pazienti affetti da SSc. Questi
pazienti hanno un rischio più elevato di sviluppare ipertensione polmonare ad un follow-up
a medio-lungo termine. L’ecocardiografia da sforzo, associata al dosaggio del BNP, si è
quindi dimostrata utile nell’identificare i pazienti  con Ssc, asintomatici o paucisintomatici,
che,  presentando un’anomalo incremento della PAPs con l’esercizio,  possono sviluppare
ipertensione polmonare a medio-lungo termine.
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SUMMARY
Background. Systemic Sclerosis (SSc) is a chronic multisystem disease characterized by
fibrosis  of the skin and internal organs,  microangiopathy and autoimmune disturbance.
Pulmonary arterial  hypertension (PAH) is  one of the most  severe complications of the
disease, carrying a poor prognosis. Because of the aspecificity of the symptoms, diagnosis
is often made when the disease is in an advanced stage and the pulmonary vascular bed
involvement is already severe. For this reason it is essential to develop suitable screening
tools to early detect the pathology, providing an appropriate therapy, that could improve
the prognosis.  
Aim of  the  study. To  evaluate  the  pulmonary  arterial  systolic  pressure  (PAsP)  during
exercise echocardiography in a  group of  asymptomatic  or mildly symptomatic  patients
affected to SSc. Patients were then submitted to a medium-long term follow-up performing
a resting echocardiogram to evaluate the development of pulmonary hypertension, defining
the predictive value of the exercise echocardiography to early identify such complication.  
Material and methods. 40 patients affected by SSc (33 females and 7 males) with NYHA
functional  class  I  and  II  and  with  normal  PAsP  at  rest,  underwent  exercise
echocardiography. Resting and exercise PAsP values were estimated through measurement
of tricuspidal regurgitant jet velocity by Doppler, considering values of exercise PAsP ≥ 48
mmHg  to  be  pathological.  We  also  analysed  resting  and  exercise  hemodynamic
parameters, clinical characteristics of the patients and of the underlying rheumatic disease
as well as measurement of resting and exercise BNP values. A medium-long term follow-
up  was  done  (5,1  ±  0,4  years),  performing  a  clinical  and  resting  echocardiographic
evaluation to detect the development of pulmonary hypertension. 
Results.  Resting PAsP values  were  26,5 ± 4,6 mmHg, reaching values  of  45,1 ± 14,2
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mmHg during exercise (p 0,00), with a mean increase of 18,7 ± 11,9 mmHg. 25 patients
(62,5%) had normal values of exercise PAsP (group A), whereas 15 patients (37,5%), all
women,  had  exercise-induced  altered  pulmonary  vasoreactivity  (group  B).  Comparing
group A and B, we found significant differences regarding both resting and exercise PAsP
values (respectively p 0,007 and p 0,00), but also regarding exercise BNP values and the
variation between resting and exercise BNP (respectively p 0,02 and p 0,001). Out of 40
initial patients, 2 patients died because of extracardiac causes, and 2 patients were lost;
therefore 36 patients were followed for a mean time of 5,1 ± 0,4 years. Data from follow-
up showed mean resting PAsP of  29,67 ± 7,4 mmHg. 5 patients, belonging to group B,
presented pathological resting PAsP values: 3 of these patients had PAsP values suggestive
for  the  diagnosis  of  possible  pulmonary  arterial  hypertension  (PAsP >  37  mmHg),  2
patients  had  PAsP values  suggestive  for  the  diagnosis  of  probable  PAH  (PAsP >  50
mmHg). None of the group A patients developed pathological PAsP values at follow-up.  
Conclusions. Prevalence of exercise-induced altered pulmonary vasoreactivity, detected by
exercise echocardiography, is high in patients affected by SSc. 
Such patients  had a higher  risk for developing pulmonary hypertension at  medium- to
long- term follow-up. Exercise echocardiography, associated with BNP testing, has been
demonstrated to be useful to identify SSc patients presenting an abnormal increase of PAsP
during exercise that could, far away, develop PAH.
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INTRODUCTION
PULMONARY ARTERIAL HYPERTENSION
Definition
The first classification of the Pulmonary Hypertension (PH) come from the first World
Conference on this topic, supported by the World health Organization, held in Geneva in
the 1973.  The initial  classification designated only two categories:  Primary Pulmonary
Hypertension  and  Secondary  Pulmonary  Hypertension,  depending  on  the  absence  or
presence of risk factors or identifiable causes. In 1998 a second World Symposium was
held in Evian and the previous classification of PH was modified, introducing 5 categories.
In 2003, during the third World Symposium, held in Venice, the clinical classification was
further  modified.  Pulmonary  hypertension  was  defined  as  the  presence  of  a  mean
pulmonary artery pressure (PAsP) ≥ 25 mmHg at rest and/or > 30 mmHg during exercise,
assessed  by  right  heart  catheterization,  with  pulmonary  vascular  resistance  >  3
mmHg/L/min (Wood Units), in presence of normal or reduced values of cardiac output. On
the basis of the pulmonary capillary wedge pressure (PCWP ≤ 15 mmHg o ≥ 15 mmHg),
two different forms of PH were distinguished: the precapillary and the postcapillary forms.
During the fourth Symposium on PH held in Dana Point, in 2008, a new definition of PH
was done.  Moreover, the importance to distinguish the pulmonary arterial  hypertension
(PAH) from the other forms of PH was also highlighted [1].
The new definition of PH was based on the presence of a mean PAsP ≥ 25 mmHg at rest,
no more including the value during exercise, because there were not, certain criteria to
identify pathologic values of PAsP during the exercise, due to the extreme variability and
influence of these values by the age, weight, cardiac output, type of the exercise [2].
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    Table 1. Haemodynamic definitions of pulmonary hypertension.
           Definition                              Characteristics                     Clinical group(s)
Pulmonary hypertension                  Mean PAP                             All
(PH)                                                       ≥25 mmHg
Pre-capillary PH                             Mean PAP                             1. Pulmonary arterial
                                                               ≥25 mmHg                          hypertension
                                                        PWP ≤15 mmHg                  3. PH due to lung disease
                                                        CO normal or reduceda        4. Chronic 
                                                                                                            thromboembolic PH
                                                                                                     5. PH with unclear and/or
                                                                                                            multifactorial
                                                                                                            mechanisms   
Post-capillary PH                           Mean PAP                             2. PH due to left heart
                                                         ≥25 mmHg                               disease
                                                       PWP >15 mmHg    
                                                       CO normal or reduceda 
                 Passive                          TPG ≤ 12 mmHg
                 Reactive (out of            TPG > 12 mmHg
                      proportion)                  
     All values measured at rest.
     aHigh CO can be present in cases of hyperkinetic conditions such as systemic-to-pulmonary shunts 
     (only in the pulmonary circulation), anaemia, hyperthyroidism, etc.
     CO = cardiac output ; PAP = pulmonary wedge pressure; TPG = transpulmonary
     pressure gradient (mean PAP – mean PWP).
     From: Galiè N et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension. 
     Eur Heart J 2009;30:2497-2537.
   Table 2. Important definitions.
- Pulmonary hypertension (PH) is a  haemodynamic and pathophysiological condition
defined as an increase in mean pulmonary arterial pressure (PAsP) ≥ 25 mmHg at rest as
assessed by right heart catheterization. PH can be found in multiple clinical conditions.
- The definition of PH on exercise as a mean PAsP >30 mmHg as assessed by right heart
catheterization is not supported by published data. 
- Pulmonary arterial hypertension (PAH, group 1) is a  clinical condition characterized
by the presence of pre-capillary PH in the absence of other causes of pre-capillary PH
such as PH due to lung disease, chronic thromboembolic PH, or other rare diseases.
PAH includes different forms that share a similar clinical picture and virtually identical
pathological changes of the lung microcirculation 
    From: Galiè N et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension. 
    Eur Heart J 2009;30:2497-2537.
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Physiology and anatomy of the pulmonary circulation
From the embryological point of view the common pulmonary artery and the two main
branches derived from the primitive cardiac tube,  meanwhile  the peripheral  pulmonary
arteries derived from a vascular network around the bronchial buds. From the pulmonary
artery trunk towards the capillaries, four types of vessels are present: 
● Elastic arteries: the common trunk of the pulmonary artery and the first 5 series of the
branches are elastic vessels (although in a lesser extent than the aorta e its main branches).
The following 3 series of branchings are considered  transitional types of vessels;
● Muscular arteries: this type represents the majority of the pulmonary vessels, up to a
diameter of 150-200 micron; they have a continuous muscular layer (tunica muscolaris),
that is however thinner than that of the systemic arteries;
● Partially muscularized arterioles: they have an incomplete muscular layer, alternated to a
capillary-like wall;
● Non-muscular  arterioles:  they lack of  smooth muscle cells,  have a  caliber  of 30-75
micron; they terminate into a capillary network of the alveolar unit and are involved in the
respiratory gas exchanges. 
The muscular and partially muscular arterioles represent the resistance vessels system and
accompany  the  respiratory  bronchioles  and  the  alveolar  ducts.  At  this  level  there  are
pericytes, that are cells able to differentiate into smooth muscle cells in the presence of an
hypoxic stimulus, thereby they constitute the site of vascular remodeling involved in the
pathogenesis of PH.   
The  lung  has  a  dual  arterial  circulation,  derived  from  the  bronchial  arteries  and  the
pulmonary arteries, and a dual venous drainage system involving the pulmonary veins and
the azygos veins. Into the lungs, every pulmonary artery accompanies the branching of the
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bronchial tree and divides at the level of the bronchial bifurcations, up to the respiratory
bronchioles. 
The pulmonary circulation is,  in the adult,  a low resistance and very high capacitance
system as compared with the systemic circulation.  All  the pulmonary artery tree has a
larger  vessels  section  than  the  systemic  district.  Moreover  it  lacks  the  high  resistance
muscular arterioles in the peripheral districts and the pulmonary capillaries are numerous
and  widely  anastomized.  For  these  reasons  pulmonary  circulation  has  a  low  pressure
gradient. The systolic and diastolic pulmonary artery pressures are about 22 and 10 mmHg,
and the mean pulmonary artery pressure is about 15 mmHg. These values are much lesser
than those measured in the aorta, because the pulmonary vascular resistance is only 1/10th
of the systemic one. Pulmonary vascular resistance in the adults is about 1 Wood Units (1
WU = 67 ± 23 dyne-sec/cm-5). With exercise the pulmonay blood flow bed increases also
five times, without a significant pressure increase. This is due to the activation of two
mechanisms: 
● Increase and distension of the vessels caliber, especially in the basal regions;
● Recruitment of the hypoperfused vasal districts, especially in the apical regions (the, so-
called, pulmonary vascular reserve).
Moreover the pulmonary vascular resistance (PVR) is regulated by some factors that act to
the  vascular tone. Neurogenic, hormonal and chemical factors are involved to the vascular
tone regulation acting to the muscular and fibroelastic elements of the vessels wall: non-
adrenergic and non-cholinergic Neuropeptides (Angiotensin II, Atrial Natriuretic Peptide,
Intestinal  Vasoactive  Peptide),  the  Autacoids  (Histamine,  Serotonin,  Bradykinin),  the
Prostaglandins with the both vasoconstriction and vasodilation actions, the Nitric Oxide
(NO) produced by the pulmonary endothelium, with the vasodilation, antiproliferative and
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antithrombotic effects, and the Endothelin with a vasoconstriction effect.  
The alveolar hypossia is a strong stimulus for the pulmonary arteriolar vasoconstriction:
this is a regulatory mechanism of the pulmonary circulation that acts to reduce the blood
flow through the hypoventilated alveoli, in favour of the normoventilated ones, to reduce
the  ventilation/perfusion  mismatch.  The  acidosis  causes  vasoconstriction  too,  acting
together with the hypoxia. A prolonged vasoconstriction leads to structural alterations in a
short time: the arteriolar wall undergoes the hypertrophy of tunica media, the appearance
of  muscolar  elements  more  peripherally  and the  tunica  intima hypertrophy.  Hence  the
global cross-sectional area of the pulmonary vascular bed reduces, the arterial stiffness
increases, resulting in peripheral pulmonary vascular resistance and pulmonary pressure
increase. 
Clinical classification of Pulmonary Hypertension
The last classification recommended during the fourth World Symposium on Pulmonary
Hypertension mantained the general organization of the previous classification,  making
some changes in specific points (Table 3).
The five groups are the following:
● Pulmonary arterial hypertension (PAH)
● Pulmonary hypertension secondary to left heart disease
● Pulmonary hypertension due to lung diseases and/or hypoxia
● Chronic thromboembolic pulmonary hypertension (CTPH)
● Pulmonary hypertension with unclear or multifactorial mechanisms
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  Table 3. Updated clinical classification of pulmonary hypertension (Dana Point, 2008).
1  Pulmonary arterial hypertension (PAH)
1.1 Idiopathic
1.2 Heritable
    1.2.1 BMPR2
    1.2.2 ALK1, endoglin ((with or without hereditary haemorrhagic telangiectasia)
                          1.2.3 Unknown
                          1.3 Drugs and toxins induced
                          1.4 Associated with (APAH)
                          1.4.1 Connective tissue diseases
                          1.4.2 HIV infection
                          1.4.3 Portal hypertension
                          1.4.4 Congenital heart disease
                          1.4.5 Schistosomiasis
                          1.4.6 Chronic haemolytic anaemia
                          1.5 Persistent pulmonary hypertension of the newborn
1'  Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
2  Pulmonary hypertension due to left heart disease
                       2.1 Systolic dysfunction
                       2.2 Diastolic dysfunction
                       2.3 Valvular disease
3  Pulmonary hypertension due to lung disease and/or hypoxia
                      3.1 Chronic obstructive pulmonary disease
                      3.2 Interstitial lung disease
                      3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
                      3.4 Sleep-disordered breathing
                      3.5 Alveolar hypoventilation disorders
                      3.6 Chronic exposure to high altitude
                      3.7 Developmental abnormalities
4  Chronic thromboembolic pulmonary hypertension 
5 PH with unclear and/or multifactorial mechanisms
                     5.1 Haematological disorders: myeloproliferative disorders, splenectomy.
                     5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis,
                           lymphangioleiomyomatosis, neurofibromatosis, vasculitis
                     5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
                     5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
          ALK-1 = activin receptor-like kinase 1 gene; APAH = associated pulmonary arterial hypertension; 
        BMPR2 = bone morphogenetic protein receptor, type 2;
        HIV = human immunodeficiency virus; PAH = pulmonary arterial hypertension.
    From: Galiè N et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension. 
    Eur Heart J 2009;30:2497-2537.
In the group 1 the term familial PAH was replaced by the term heritable PAH, because
specific gene mutations have been identified in sporadic cases without a family history.
Therefore the heritable form of PAH includes both the sporadic and the familial cases. In
group 1 there are also the idiopathic PAH (IPAH), the drug and toxins induced PAH, the
                                                                      15
persistent pulmonary hypertension of the newborn and the form associated with various
clinical conditions (APAH): connective tissue diseases, HIV infection, portal hypertension,
congenital heart disease, schistosomiasis and chronic haemolytic anaemia (such as sickle
cell disease, thalassaemia, hereditary spherocytosis, stomatocytosis, and microangiopathic
haemolytic anaemia).  
In  the  group  1'  pulmonary  veno-occlusive  disease  and  pulmonary  capillary
haemangiomatosis  remain  difficult  disorders  to  classify  since  they  share  some
characteristics with IPAH, but also demonstrate a number of differences. So the consensus
agreement of experts decided that these conditions should be a distinct category, but not
completely separated from PAH, and have been designated as clinical group 1'. 
Group 2 includes PH due to left heart disease (systolic, diastolic dysfunction or valvular
diseases)  and  group  3  PH  due  to  lung  diseases  and/or  hypoxia  (chronic  obstructive
pulmonary disease, interstitial lung disease, etc.).
Group  4  is  chronic  thromboembolic  PH,  secondary  to  proximal  or  distal  obstructive
lesions,  caused by thromboemboli (CTEPH). 
Group 5 comprises  a  heterogeneous collection  of  diseases  with  uncertain  pathogenetic
mechanisms leading to PH, including haematological, systemic, metabolic, and other rare
disorders.  
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Hystopathology and pathogenesis
Although the clinical, hemodynamic and prognostic aspects of the different forms of PAH
are  rather  heterogeneous,  they  share  the  same  hystopathological  substrate  that  is
represented by a wide spectrum of proliferative and obstructive lesions of the pulmonary
vessels defining the pulmonary  hypertensive arteriopathy. 
The pathological process mostly involves the peripheral pulmonary arteries, such as the
preacinar and intraacinar muscular arterioles (resistance vessels), but it could also involve
the venous and capillary district. 
The  pulmonary  hypertensive  arteriopathy  is  characterized  by  the  following  structural
lesions:
• Hypertrophy of the tunica media
• Thickening of the tunica intima 
• Thickening of the tunica adventitia 
•Complex obstructive endoluminal lesions with reparative and with reparative/proliferative
characteristics.
Tunica media hypertrophy is a diffuse process, common to all type of PAH, due to both the
hypertrophy and hyperplasia of the smooth muscle cells, the increase of the elastic fibres
and of the connective tissue.  
The thickening of the tunica intima is caused by the intimal cells proliferation and is an
obliterative diffuse lesion, frequent in all type of PAH. The ticknening can be: concentric
laminar, concentric non-laminar or eccentric.
The thickening of the tunica adventitia  is  caused by the perivascular  connective tissue
hypertrophy, stimulated by growth factors. It is responsible for the increased stiffness of
the vessel wall. 
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The complex endoluminal lesions are reparative and proliferative alterations and include
the plexiform lesions, the angiomatoid lesions and the necrotizing arteritis.
The  plexiform  lesions  are  focal  alterations,  comparable  to  renal  glomeruli,  and  are
constituted  by  a  plexus  of  capillaries,  frequently  associated  to  thrombi.  They  are
characterized  by  highly  proliferative  endothelial  cells  surrounded  by  myofibroblasts,
smooth muscle cells and connective tissue. The angiomatoid lesions are very thin, dilated
and  tortuous  vascular  structures  often  localized  distal  to  the  plexiform  lesions.  The
necrotizing  arteritis  is  characterized  by  segmental  fibrinoid  necrosis  of  the  muscular
arterioles with inflammatory cells infiltration. 
In  PAH  the  hystological  examination  reveals  a  panvasculopathy,  affecting  the  distal
arterioles (with a diameter  < 500 micron); it is present intimal fibrosis and hypertrophy,
smooth  muscle  cells  hypertrophy,  vasoconstriction,  adventitial  thickening  with
inflammatory perivascular infiltrates, plexiform lesions and in situ thrombosis. Over time
these alterations cause the obstruction of the blood flow within the vessels, together with
disorganized  angiogenesis  and  plexiform  arteriopathy.  The  process  that  causes  these
pathological changes is not known, however the common opinion is that the etiology of the
PAH is multifactorial, with both a substrate of genetic and constitutional predisposition and
some environmental factors (toxins exposure, infective or inflammatory processes, etc.).  
The processes responsable for the vascular resistance increase in PAH are:
● Obstructive vascular remodeling  
● Vasoconstriction
● Inflammation
● Thrombosis
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              Figure 1. Histology in pulmonary arterial hypertension. 
                                                             a                                                                     b          
           c d
                                                                                                                                  
                                                              e                                                                  f
     
     Figure 2. Proliferative lesions of the tunica intima. Plexiform lesion (figure a). Lesions are rich of 
      cells (figure b) with fibrosis and elastic fibres proliferation (figure c); occlusion of the vessel lumen 
      due to fibrosis (figure d); fibrinoid necrosis (arrows, figure e); arteritis (figure f).
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The obstructive vascular remodeling is considered the key element in the  pathogenesis
of PAH. The obstructive lesions involve all the vascular layers and various type of cells
(endothelial cells, smooth muscle cells and fibroblasts). The histopathological hallmark of
vascular remodeling is the anomalous and disorganized cellular proliferation leading to an
increased thickness of the vessel wall. Many growth factors are considered involved in the
vascular remodeling process: an increased expression of vascular endothelial growth factor
(VEGF),  platelet  derived growth factor  (PDGF),  fibroblast  growth factor  beta  (bFGF),
insuline-like growth factor 1 (IGF-1), epidermal growth factor (EGF), and angiopoietin-1
(that is an important angiogenetic factor for the development of the pulmonary vascular
bed) have been found in the lung tissues of patients affected by PAH.  
Vasoconstriction mechanisms seem to be related to the abnormal function or expression of
potassium channels in the smooth muscle cells and to endothelial dysfunction. The latter
causes a reduced production of vasodilator agents such as nitric oxide, prostacyclin and
vasoactive intestinal peptide (VIP), and an over-expression of vasoconstriction substances
such as thromboxane-A2, endothelin-1 and serotonin (5-HT).  
The prostacyclin is a potent pulmonary vasodilator agent that inhibits the smooth muscle
cells  proliferation  and  reduces  the  platetel  aggregation  through  cyclic  AMP (cAMP)
pathway activation.  Nitric  oxide  is  a  additional  potent  pulmonary vasodilator  and acts
through  cyclic  GMP  (cGMP)  pathway.  Endothelin-1  exerts  its  action  of  potent
vasoconstriction, and pulmonary vessels smooth muscle cells proliferation interacting with
two types  of  receptors  (ETA and ETB). 5-HT is  a  substance produced by the intestinal
enterochromaffin cells and stored in plateles, and it induces vasoconstriction and smooth
muscle cells proliferation. VIP is a neurotransmitter acting through the cGMP and cAMP
pathway activation: it induces systemic and pulmonary vasodilation and inhibits smooth
muscle cells proliferation and platetel aggregation. 
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The evidence of inflammatory processes in PAH is given by the hystological finding of
accumulation of perivascular inflammatory cells including macrophages, dendritic cells, T
and B lymphocytes. Moreover circulating levels of certain cytokines and chemokines are
elevated.  
Thrombosis  and  platelet  dysfunction  are  also  involved  in  the  pathogenesis  of  the
pulmonary hypertensive vasculopathy. Patients affected to PAH have a thrombophilic state
and thrombotic  lesions  are  present  in  both the small  distal  pulmonary arteries and the
proximal elastic pulmonary arteries. The platelet dysfunction role in PAH is not limited to
altered coagulation process. Actually, in response to specific stimuli, platelets are able to
produce prothrombotic, vasoactive and mitogen factors as thromboxane A2, PDGF, 5-HT,
TGF-  and VEGF, which contribute to vascular remodeling . 
Genetics, epidemiology and risk factors
Currently, there are not reliable epidemiological data about the prevalence of the different
groups  of  PH,  but  a  survey,  performed  in  an  echocardiography  laboratory,  showed  a
prevalence of PH (defined as PAsP > 40 mmHg), among 4579 patients, of 10,5% [3].
In 78,7% of cases, PH was secondary to left heart diseases, in 9,7% secondary to lung
diseases  or  hypoxia,  4,2%  had  PAH  (Group  1),  and  in  0,6%  PH  was  secondary  to
thromboembolism. Finally, in 6,8% of cases an aetiology was not ascertained. 
In the presence of a familial form of PAH, germline mutation in the bone morphogenetic
protein receptor 2 (BMPR2) gene is found in 70% of cases. This protein is involved in the
control of vascular cell proliferation processes. Such mutation is also found in 11-40% of
sporadic cases, thus resulting in major genetic predisposing factor for PAH. 
Data obtained by the European countries registries show a prevalence of PAH of about 15-
50 cases per million population in Europe [4]. In the French registry, 39,2% of cases had
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IPAH, in 3,9% there was a family history of PAH. Among the forms of PAH associated to
other clinical conditions, the 15,3% of cases had a connective tissue disease (CTD), mostly
the systemic sclerosis, 11,3% a congenital heart disease (CHD), 10,4% portal hypertension,
in 9,5% there was the anorexigen-assciated PAH, and 6,2% had HIV infection [5].
Prevalence of PAH in the general population
15–50 cases per million (0.0015–0.0050%)
Prevalence of PAH in at risk populations
Congenital heart disease: 4–15%
Systemic sclerosis: 8–10%
Portal hypertension: 0.5–10%
HIV: 0.5%
Sickle cell disease: 2%
BMPR2 mutations carriers: 20%
   PAH, pulmonary arterial hypertension; CHD, congenital heart disease; 
   HIV, human immunodeficiency virus; BMPR2, bone morphogenic protein receptor 2.
   From: Lau E et al. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: 
            time to move forward. Eur Heart J 2011; 32:2489–2498.
Clinical presentation and diagnosis
The evaluation process of a patient with suspected PH requires a series of investigations
intended  to  confirm  the  diagnosis,  clarify  the  clinical  group  of  PH  and  the  specific
aetiology  within  the  PAH  group,  and  evaluate  the  functional  and  haemodynamic
impairment. Diagnosis of PH is often made very late, because symptoms are non-specific,
so an high level of clinical suspicion may be necessary. 
Moreover,  since PAH, and particularly IPAH, is  a diagnosis  of  exclusion,  a  diagnostic
algorithm may be useful (Fig.11). First of all, the most common causes of PH, such as left
heart  diseases  and  lung  diseases,  should  be  investigated;  thereafter  thromboembolic
aetiology should be excluded and, at the end, the most rare causes of PH (group 5).   
The  symptoms are  non-specific  and include  breathlessness,  fatigue,  weakness,  angina,
syncope. Symptoms at rest are reported only in very advanced cases.   
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    Figure 3. Schematic representation of the relationship between pulmonary microcirculation loss 
     and PAP. The high capacitance of the pulmonary circulation implies that early microcirculation loss 
     is not accompained by a change in resting PAP. Many of the current screening modalities are dependent  
     on detecting a rise in PAP, and thus will fail to detect the early stages of PVD.
     PAP:pulmonary artery pressure; PVD: pulmonary vascular disease; RV: right ventricle. 
     PAH: pulmonary arterial hypertension; PVR: pulmonary vascular resistance; CO: cardiac output; 
      From: Lau E et al. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: 
                time to move forward. Eur Heart J 2011; 32:2489–2498.
Exercise capacity is classified into 4 classes according to the World Health Organization
(OMS),  redefined in 1998 [6,7]. 
Class I Patients with PH without resulting limitation of physical activity. Ordinary 
physical activity Ordinary physical activity does not cause undue dyspnoea 
or fatigue, chest pain, or near syncope. 
Class II Patients with pulmonary hypertension resulting in slight limitation of 
physical activity. They are comfortable at rest. Ordinary physical activity 
causes undue dyspnoea or fatigue, chest pain, or near syncope.
Class III Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activity 
causes undue dyspnoea or fatigue, chest pain, or near syncope.
Class IV Patients with pulmonary hypertension and inability to carry out any physical 
activity without symptoms. These patients manifest signs of right heart 
failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is 
increased by any physical activity.
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The  physical signs include left parasternal lift, an accentuated pulmonary component of
second heart sound, a pansystolic murmur of tricuspid regurgitation, a diastolic murmur of
pulmonary insufficiency and a right ventricular third sound. Signs of right heart failure
(jugular  vein  distension,  hepatomegaly,  peripheral  oedema  and  ascites)  characterized
patients in a more advanced state.  
The electrocardiogram has  a  specificity  of  55%  and  a  sensitivity  of  70%  to  be  a
screening tool for detecting PH. In advanced stages may be present signs of right atrial
dilatation,  right  ventricular  hypertrophy  and  right  axis  deviation.  Moreover,
supraventricular  arrhythmias  (atrial  flutter  and  atrial  fibrillation)  are  frequent,  whereas
ventricular arrhythmias are rare. 
Chest radiograph, in 90% of patients with IPAH, is abnormal at the time of diagnosis.
Findings include central pulmonary arterial dilatation, which contrasts with ‘pruning’ (loss)
of the peripheral blood vessels. Right atrium and right ventricular enlargement may be
seen in  more advanced cases.  The chest  radiograph allows associated lung diseases  or
pulmonary venous hypertension due to left heart disease to be reasonably excluded.
Pulmonary function tests and arterial blood gases. Pulmonary function tests and arterial
blood  gases  will  identify  the  contribution  of  underlying  airway  or  parenchymal  lung
disease.  Patients  with  PAH usually have  decreased  lung diffusion  capacity  for  carbon
monoxide (typically in the range of 40–80% predicted) and mild to moderate reduction of
lung volumes. Arterial oxygen (02) tension is normal or only slightly lower than normal at
rest and arterial carbon dioxide tension is decreased because of alveolar hyperventilation. 
The  exercise  capacity  can  be  assessed  by  the  6-minute  walking  test  (6MWT)  and
cardiopulmonary  exercise  testing.  The  6MWT  is  technically  simple,  inexpensive,
reproducible, and well standardized. In addition to distance walked, dyspnoea on exertion
(Borg scale) and finger arterial O2 saturation are recorded. With cardiopulmonary exercise
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testing gas  exchange and ventilation  are continuously recorded throughout  incremental
exercise.  In PAH, O2 uptake at the anaerobic threshold and peak exercise are reduced in
relation to disease severity, as are peak work rate, peak heart rate, O2 pulse, and ventilatory
efficiency. The 6MWT remains until now the only Food and Drug Administration- and
European Agency for the Evaluation of Medicinal Products-accepted exercise endpoint for
studies evaluating treatment effects in PAH, because a generally accepted standardization
of cardiopulmonary exercise testing is lacking.  
Transthoracic echocardiography provides several variables which correlate with right
heart  haemodynamics  including PAsP,  and should always  be  performed in the  case  of
suspected PH. The estimation of PAsP is based on the peak velocity of the jet of tricuspid
regurgitation.  The  simplified  Bernoulli  equation  describes  the  relationship  of  tricuspid
regurgitation velocity and the peak  pressure gradient of tricuspid regurgitation: tricuspid
regurgitation pressure gradient=4x(tricuspid regurgitation velocity)2. This equation allows
for estimation of PA systolic pressure taking into account right atrial pressure: PA systolic
pressure = tricuspid regurgitation pressure gradient + estimated right atrial pressure. Right
atrial  pressure  can  be  estimated  based  on  the  end-expiratory  diameter  and  respiratory
variation of the inferior vena cava (measured 0,5-3 cm from its junction to right atrium),
although often a fixed value of 5 or 10 mmHg is assumed (Table 1 and 2).
  Table 1. Estimation of right atrial pressure.
                IVC: inferior vena cava; RA: right atrium; E/E': ratio between E and E'wave of diastolic flow.
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Table  2.  Arbitrary  criteria  for  estimating  the  presence  of  PH  based  on  tricuspid
regurgitation peak velocity and Doppler-calculated PA systolic pressure at rest (assuming a
normal right atrial pressure of 5 mmHg) and on additional echocardiographic variables
suggestive of PH.
Classe Livello
Echocardiographic diagnosis: PH unlikely 
Tricuspid regurgitation velocity 2.8 m/s, 
PA systolic pressure 36 mmHg, and no
additional echocardiographic variables
suggestive of PH
I B
Echocardiographic diagnosis: PH possible
Tricuspid regurgitation velocity 2.8 m/s, 
PA systolic pressure 36 mmHg, but presence of
additional echocardiographic variables
suggestive of PH
Tricuspid regurgitation velocity 2.9–3.4 m/s, 
PA systolic pressure 37–50 mmHg with/without
additional echocardiographic variables
suggestive of PH
IIa
IIa
C
C
Echocardiographic diagnosis: PH likely
Tricuspid regurgitation velocity .3.4 m/s, 
PA systolic pressure .50 mmHg, with/without
additional echocardiographic variables
suggestive of PH
I B
Exercise Doppler echocardiography is not
recommended for screening of PH III C
  From: Galiè N et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension. 
             Eur Heart J 2009;30:2497-2537.
However there are some limitations in the Doppler-derived pulmonary pressure estimation:
when  peak tricuspid regurgitation velocity is  difficult  to  measure (trivial/mild tricuspid
regurgitation)  the  use  of  contrast  echocardiography  (e.g.  agitated  saline)  significantly
increases the Doppler signal, allowing proper measurement of peak tricuspid regurgitation
velocity;  moreover  this  technique  is  an  operator-dependent   procedure.  Both
overestimations or underestimations of systolic PAP can occur. Some studies showed a
good correlation between echocardiographic estimation of systolic PAP and its invasive
measurement  by  right  heart  catheterization  (RHC)  [8,9],  while  others  have  revealed
differencies  between  the  two  methods:  35%  of  cases,  and  45%  of  cases  of
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echocardiographic diagnoses of PH were falsely positive [10,11].
These differencies can be due to low operator experience, a poor Doppler alignment with
the tricuspid regurgitant jet,  an incorrect estimation of right atrial  pressure,  but also to
different and variable haemodynamic conditions.  
 Figure 4. Doppler tricuspid regurgitant jet velocity.
The echocardiographic evaluation also allows the estimate of the mean PAP through the
pulmonary valve regurgitant flow analysis, the acceleration time of the pulmonary artery
that correlates to mean PAP and PVR, and the estimation of the pulmonary artery end-
diastolic pressure using the end-diastolic pulmonary regurgitant jet added to right atrial
pressure estimate.                                                                                                                                           
  Figure 5. Continuous Doppler pulmonary  regurgitant    Figure 6. Pulsed Doppler pulmonary artery
                jet velocity.                                                                           flow velocity.                                   
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Numerous studies are present in licterature showing how to estimate left atrial pressure and
left ventricular filling pressure using the echocardiography [12-14].
The more useful parameters are: E/E' ratio, pulmonary veins flow analysis using pulsed
Doppler. E/E' is a ratio between the lef ventricle early diastolic flow velocity, measured by
pulsed Doppler at the level of the mitral valve (E wave), and the early diastolic velocity of
the  mitral  annulus  measured  by  tissue  Doppler.  An  E/E'  ratio  >  15  is  suggestive  of
increased left ventricular diastolic pressures, whereas a E/E' ratio < 8 accurately predicts
normal left ventricular filling pressures.  E/E' values 8 to 15 represent a grey-zone, where
the diagnosis is uncertain. Analysing pulmonary venous flow, peak systolic (S wave) and
early diastolic (D wave) flow velocities of the pulmonary flow have a normal pattern when
the S/D ratio is between 1,3 and 1,5 (± 0,3), with a systolic fraction (a ratio of velocity-
time integral of the S wave to the sum of velocity-time integrals of the D wave and S
wave) of 60-68%; S/D ratio < 1 is suggestive of mean left atrial pressure  ≥ 15 mmHg,
with a sensitivity of 90% and a specificity of 85%.           
Figure 7. Pulsed Doppler pulmonary venous flow (Systolic, S and diastolic, D waves).
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Figure 8 and 9.   Septal and lateral mitral annulus tissue Doppler.           
Pluriparametric evaluation of the diastolic function can identify the presence of left heart
dysfunction with altered compliance of the left cavities, that is one of the causes of PH
(group 2).  Echocardiographic parameters useful for the right ventricular systolic function
evaluation  are:  right  ventricular  fractional  area  change  (RVFAC),  TAPSE  (Tricuspid
annular plane systolic excursion) and TAV (tricuspid annular velocity).
The fractional shortening is the percentage change of the right ventricular area between the
end-diastole  (EDA)  and  the  end-systole  (ESA),  expressed  with  the  formula  (EDA-
ESA/EDA). Normal values of RVFAC are 56 ± 13%. TAPSE is useful for the assessment
of the right ventricular longitudinal function and it is measured by M-mode technique at
the  lateral  tricuspid  annulus  in  apical  4-chamber  view.  Values  ≥ 16 mm are  generally
normal. TAV records the systolic movement of the lateral tricuspid annulus using tissue
Doppler: normal values of the systolic peak velocity (S') are > 12 cm/sec.    
                                      Figure 10. Right ventricle lateral tricuspid annulus tissue Doppler.
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The right ventricular diastolic function can be evaluated by the ventricular filling pattern
analysis, using pulsed Doppler between the opened tricuspid leaflets in diastole. The flow
velocities registered at this level are lower than that of the left heart chambers and there are
more respiratory variability. 
E/E' ratio of the tricuspid valve and annulus has a good correlation with the mean right
atrial  pressure.  E/A ratio  (of  the  tricuspid  diastolic  flow),  E/E'  ratio  and  right  atrial
dimension are the more reliable parameters for the study of the right ventricular diastolic
function. E/A ratio < 0,8  suggest the presence of diastolic impaired relaxation, E/A ratio
between 0,8 and 2,1 associated to E/E' ratio > 6 has a sensitivity of 79% and a specficity of
73% to estimate a right atrial pressure > 10 mmHg. E/A ratio > 2,1, with a deceleration
time of the E wave < 120 msec is a restrictive pattern [15].
Exercise echocardiography is a technique not validated for the diagnosis of PH because it
lacks a clear cut-off values to make the diagnosis and data have not been validated and
compared  to  right  heart  cateterization  results  (class  III  of  recommendations,  level  of
evidence C, according to the latest guidelines) [7].
However many studies are still being performed using this technique, on the basis of the
concept that it  could be possible to disclose,  with the exercise,  conditions of impaired
pulmonary vascular reserve, that coul be a preclinical stage of the pulmonary hypertensive
disease [16].
Regarding  blood tests, it is important to make serological screening for HIV, antibodies
assay  (Antinuclear,  anti-centromere,  anti-Scl70,  and  antiphospholipid  antibodies),
thrombophilia screening, and liver and thyroid function tests. 
Natriuretic peptides (BNP, e NT-proBNP) are useful in  the diagnosis  and follow-up of
patients with heart failure, and are also correlated with prognosis of these patients [17].
Right heart catheterization (RHC) is required to confirm the diagnosis of PAH, to assess
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the  severity  of  the  haemodynamic  impairment  and  to  test  the  vasoreactivity  of  the
pulmonary circulation. When performed at experienced centres, RHC procedures have low
morbidity (1,1%) and mortality (0,055%) rates. The following variables must be recorded
during RHC: PAP (systolic, diastolic and mean), right atrial pressure, pulmonary wedge
pressure, right ventricular pressure, and cardiac output (CO).  
Vasoreactivity  testing  should  be  performed  at  the  time  of  diagnostic  RHC to  identify
patients  who  may  benefit  from  long-term  therapy  whith  calcium  channel  blockers.
According  to  the  latest  guidelines,  vasoreactivity  test  is  indicated  with  a  class  of
recommendation  IC,  in  patients  with  idiopathic,  heritable  or  anorexigen use-associated
PAH. Currently the agent most used in acute testing is NO; intravenous epoprostenol or
adenosine may also be used as an alternative. A positive acute response (positive acute
responder) is defined as a reduction of mean PAP ≥ 10 mmHg to reach an absolute value of
mean PAP ≤ 40 mmHg, with an increased or unchanged cardiac output (CO). Positive
acute responders are most likely to show a sustained response to long-term treatment with
high doses of calcium channels blockers, especially if they are affected by the idiopathic
form of PAH.  
High-resolution computed tomography (HRCT) provides  detailed  views of  the  lung
parenchyma and facilitates the diagnosis of interstitial lung disease and emphysema.  
Contrast  CT  angiography  and  pulmonary  angiography is  helpful  in  determining
whether  there  is  evidence  of  surgically  accessible  CTEPH  (suitability  for  pulmonary
endarterectomy).
Cardiac  magnetic  resonance  is  not  recommended  in  the  diagnostic  algorithm of  the
guidelines,  but  could  provide  morphologic  and  functional  informations  of  the  right
ventricle. 
Ventilation/perfusion lung scan  remains  the  screening  method  of  choice  for  CTEPH
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because of its high sensitivity. 
Diagnostic algorithm (Figure 11). Diagnostic process starts with the identification of the
more  common  clinical  groups  of  PH  (group  2:  left  heart  disease  and  group  3:  lung
diseases),  then  distinguishes  group  4:  CTEPH  and  finally  makes  the  diagnosis  and
recognizes the different types in group 1 and the rarer conditions in group 5.
PAH should be considered in the differential diagnosis of exertional dyspnoea, syncope,
angina, and/or progressive limitation of exercise capacity, particularly in patients without
apparent  risk  factors,  symptoms  or  signs  of  common  cardiovascular  and  respiratory
disorders.  Special  awareness  should  be  directed  towards  patients  with  associated
conditions and/or risk factors for development of PAH such as family history, CTD, CHD,
HIV infection, portal hypertension, haemolytic anaemia, or a history of intake of drugs and
toxins known to induce PAH. In everyday clinical practice such awareness may be low.
More often PH is  found unexpectedly on transthoracic  echocardiography requested for
another indication.  
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Figure 11. Diagnostic algorithm.  ALK-1 = activin-receptor-like kinase;  ANA = anti-nuclear  antibodies;
BMPR2 = bone morphogenetic protein receptor 2; CHD = congenital heart disease; CMR = cardiac magnetic
resonance;  CTD  = connective  tissue  disease;  Group  = clinical  group  (Table  3);  HHT  = hereditary
haemorrhagic telangiectasia; 
HIV = human immunodeficiency virus; HRCT = high-resolution computed tomography;
LFT = liver function tests; mPAP = mean pulmonary arterial pressure; PAH = pulmonary arterial 
hypertension; PCH = pulmonary capillary haemangiomatosis; PFT = pulmonary function test; PH = 
pulmonary hypertension; PVOD = pulmonary veno-occlusive disease; PWP = pulmonary wedge pressure; 
RHC = right heart catheterization; TEE = transoesophageal echocardiography; TTE = transthoracic 
echocardiography;
US = ultrasonography; V/Q scan = ventilation/perfusion lung scan. 
From: Galiè N et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension. Eur Heart
J 2009;30:2497-2537.
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If non-invasive assessment is compatible with PH, clinical history, symptoms, signs, ECG,
chest  radiograph,  transthoracic  echocardiogram,  pulmonary  function  tests  (including
nocturnal  oximetry,  if  required),  and high  resolution  CT of  the  chest  are  requested  to
identify the presence of group 2 or group 3. If these are not found or if PH seems 'out of
proportion'  to  their  severity,  less  common  causes  of  PH  should  be  looked  for.  If  a
ventilation/perfusion  scan  shows  multiple  segmental  perfusion  defects,  a  diagnosis  of
group  4  should  be  suspected.  The  final  diagnosis  of  CTEPH  (and  the  assessment  of
suitability for pulmonary endarterectomy) will require CT pulmonary angiography, RHC,
and selective pulmonary angiography. The CT scan may also show signs suggestive of
group 1' (PVOD). If a ventilation/perfusion scan is normal or shows only subsegmental
'patchy' perfusion defects, a tentative diagnosis of group 1 or the rarer condition of group 5
is made.
Additional  specific  diagnostic  tools  including  haematology,  immunology,  serology,
biochemistry and ultrasonography will allow the final diagnosis to be refined. 
Open or  thoracoscopic  lung biopsy entails  substantial  risk of  morbidity  and mortality.
Because of the low likelihood of altering the diagnosis and treatment, routine biopsy is
discouraged in PAH patients. 
Evaluation of severity and prognostic factors
Prognosis  in  PAH depends largely on its  etiology.  A French registry showed a  1-year
survival  of these patients  of 85,7%, 2-years survival of 69,5% and 3-years survival of
54,9%.  The  US  REVEAL registry  confirmed  these  data  and  indicated  as  important
prognostic  factors  the  etiology,  the  functional  class,  sex,  reduced  exercise  capacity,
haemodynamic parameters and right ventricular function.  
The evaluation of severity of functional impairment in PAH has a pivotal role to identify
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the optimal therapeutic strategy, the response to therapy and the need of possible escalation
of therapy during the follow-up. 
Based on the clinical, non-invasive and invasive findings the clinical condition of a patient
can be defined as: 
● Stable  and  satisfactory:  patients  in  this  condition  should  fulfil  the  majority  of  the
findings  listed  in  the  'better  prognosis'  column in  table  3.  In particular,  the  patient  is
characterized  by  absence  of  clinical  signs  of  right  ventricular  failure,  stable  WHO
functional class I or II without syncope, a six-minute walking test distance > 500 m, a
peak VO2 > 15ml/min/Kg, normal  or near-normal  BNP/NT-proBNP plasma levels,  no
pericardial effusion, TAPSE > 20 mm, right atrial pressure < 8 mmHg, and a cardiac index
≥ 2,5 L/min/m2.
● Stable and not satisfactory: this is a patient who, although stable, has not achieved the
status which patient and treating physician would consider desirable. Some of the limits
described for a stable and satisfactory condition and included in the first column of table 3
are not fulfilled. These patients require re-evaluation and consideration for additional or
different treatment.
● Unstable and deteriorating: Patients in this condition fulfil the majority of the findings
listed in the ‘worse prognosis’ column of table 3. In particular the patient is characterized
by evidence of  progression of right ventricular  failure symptoms and signs,  worsening
WHO functional class, i.e. from II to III or rom III to IV, a 6 min walk distance of < 300 m,
a  peak  VO2  <  12  mL/min/kg,  rising  BNP/NT-proBNP  plasma  levels,  evidence  of
pericardial effusion, TAPSE   <  1.5 cm, right atrial pressure  >  15 mmHg and a cardiac
index that is ≤ 2.0 L/min/m2. Clinical warning signs are increasing oedema and/or the need
to escalate diuretic therapy, new onset or increasing frequency/severity of angina which
can  be  a  sign  of  deteriorating  RV function,  and  the  onset  or  increasing  frequency of
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syncope which  is  often  a  grim prognostic  sign  and requires  immediate  attention  as  it
heralds  low  output  heart  failure.  Supraventricular  arrhythmias  may  be  seen  in  this
condition and contribute to clinical deterioration.
Table 3.  Parameters with established importance for assessing disease severity, stability
and prognosis in PAH (adapted from McLaughlin and McGoon [18]).
   aDepending on age.
   bTAPSE and pericardial effusion have been selected because they can be measured in the majority 
    of the patients.
    BNP = brain natriuretic peptide; CI = cardiac index; 6MWT = 6-minute walking test; 
    RAP = right atrial pressure; TAPSE = tricuspid annular plane systolic excursion;
    WHO-FC = WHO functional class.
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PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH
CONNECTIVE TISSUE DISEASE 
PAH is a well-known complication of connective tissue diseases (CTD) such as systemic
sclerosis, systemic lupus erythematosus, mixed CTD, and, to a lesser extent, rheumatoid
arthritis,  dermatomyositis,  and  Sjögren's  syndrome.  PAH  associated  with  CTD  (about
15%) is the second most prevalent type of PAH after IPAH (about 53%) in registries [5].
Systemic sclerosis, particularly in its limited variant (CREST syndrome), represents the
main CTD associated with PAH. The prevalence of haemodynamically proven PAH in
large cohorts of patients with systemic sclerosis is between 7 and 12% [19].
In these patients, PAH may occur in association with interstitial fibrosis or as a result of an
isolated  pulmonary  arteriopathy.  For  this  reason  it  is  imperative  to  determine  which
mechanism is operative since this dictates treatment.  Histopathological changes in PAH
associated  with  CTD  are  generally  indistinguishable  from  those  of  classical  IPAH,
although  there  is  more  frequent  involvement  of  the  pulmonary  veins  [20].  The
pathophysiological mechanisms leading to PAH in patients with CTD remain unknown.
The  presence  of  antinuclear  antibodies,  rheumatoid  factor,  immunoglobulin  G,  and
complement  fraction  deposits  in  the  pulmonary  vessels  wall  suggests  a  role  of
immunological mechanisms.
Diagnosis. Compared  with  IPAH,  patients  with  CTD  and  PAH  are  mainly  women
(women/men  ratio  4:1),  are  older  (mean  age  at  diagnosis:  66  years),  may  present
concomitant disorders (pulmonary fibrosis, left heart disease), and have shorter survival
[19].  The unadjusted risk of death for systemic sclerosis-associated PAH compared with
IPAH is 2.9 [21] and the predictors of outcome are the same as for IPAH (RAP, PAP, and
CI). Symptoms and clinical presentation are very similar to those of IPAH and occasional
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patients  thought  to  have  IPAH  can  be  identified  as  having  an  associated  CTD  by
immunological screening tests. High-resolution CT is helpful for evaluating the presence
of associated interstitial lung disease. An isolated reduction of diffusion capacity of carbon
monoxide is a frequent abnormality in systemic sclerosis associated with PAH.
Echocardiographic screening for the detection of PH has been recommended annually in
asymptomatic patients with the scleroderma spectrum of diseases but only in the presence
of symptoms in other CTDs. As in other forms of PAH, RHC is recommended in all cases
of suspected PAH associated with CTD to confirm the diagnosis, determine severity, and
rule out left-sided heart disease. RHC is mandatory if targeted treatments are considered.
The proportion of responders in the acute vasodilator test is lower than in IPAH and its
clinical usefulness is unclear [22].
     Table 1. Recommendations for PAH associated with 
     connective tissue disease.
      From: Galiè N et al. Guidelines for the diagnosis and treatment of 
       pulmonary arterial hypertension. Eur Heart J 2009; 30: 2497-2537.
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SYSTEMIC SCLEROSIS
Systemic sclerosis (SSc) is a chronic multisystem disease characterized by fibrosis of the
skin and internal organs,  microangiophaty and autoimmune disturbance.  Because of its
peculiar hystopathological lesions, it is considered a systemic connective tissue disease.  
The disease was previously called  Scleroderma,  that is derived from the Geek for 'hard
skin' and emphasises the dermatological component of the disease. It was described by
Hippocrates.
Classification. Two major  subsets  are  recognized,  according  to  the  extent  of  the  skin
involvement,  namely,  SSc  with  limited  cutaneous  involvement  and  SSc  with  diffuse
cutaneous involvement [23].  
The  diffuse cutaneous form has  a  more  rapid  onset,  the  skin  changes  (thickening and
tightening) may spread rapidly within a few months of Raynaud's phenomenon onset, and
symmetrically  involves  all  the  body  surface.  Often  there  is  an  early  internal  organ
involvement and the prognosis is poor. 
The limited cutaneous form, previously called CREST syndrome (Calcinosis,  Raynaud's
disease,  Esophageal dysmotility,  Sclerodactyly,  Teleangectasia) is the more frequent type
of  SSc  (approximately  60% of  patients).  The  onset  is  characterized  by the  Raynaud's
phenomenon,  that  usually precedes  the skin involvement  by some years.  Skin changes
affects only the face, forearms and lower legs up to the knee. Internal organs are less often
affected,  and the prognosis is less severe.  However an obliterative vasculopathy of the
pulmonary arterioles can occur, leading to isolated pulmonary hypertension, without signs
of interstitial lung disease. 
Epidemiology. In Europe the annual incidence of SSc is estimated to be 10 to 20 cases per
1 million persons, whereas the prevalence is 50 cases per 1 million persons [24,25]. In US
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the incidence and prevalence are higher  [26];  African Americans are  at  grater  risk for
diffuse disease. Women are roughly four times more likely than men to develop SSc. The
diagnosis is usually made in the third or fourth decade of life. 
Etiology and pathophysiology. The pathological features of the Ssc are:
• Relevant and often progressive cutaneous and visceral fibrosis. 
• Fibroproliferative vasculopathy.
• Humoral and cell mediated immunity disorders (circulating autoantibodies). 
                   
     
            Figure 1. Pathogenetic mechanisms in SSc.    
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Etiology is unknown, but the complexity of its pathogenesis suggests that one or more
environmental agents in genetically susceptible substrate are likely to be responsible for
the  development  of  SSc.  The  pathogenesis  of  SSc  involves  endothelium,  epithelium,
fibroblasts  and  immunological  mediators,  with  cell-cell,  cell-cytokine  and  cell-matrix
interactions [27].
Most hypotheses focus on the interplay between early immunological events and vascular
changes, leading to microvascular damage and fibroproliferative vasculopathy. Endothelial
activation  causes  also  extravasation  of  inflammatory  cells,  like  macrofages,  T  and  B
lymphocyte, resulting in cytokines and growth factors production that activate a population
of fibrogenic fibroblasts generally considered to be the effetctor cells in the disease. The
autonomous activated fibroblasts continue to produce the excessive extracellular matrix
that underlies the ultimate fibrotic pathology of SSc. 
There  is  an  impairment  of  endothelium-dependent  vascular  smooth  muscle  relaxation
demonstrated by the evidence of reduced serum levels of nitric oxide and prostacyclin in
SSc. Vascular injury occurs before clinically evident fibrosis. There is an altered functional
state of the endothelium characterized by increased permeability, enhanced vasoreactivity,
enhanced  expression  of  adhesion  molecules,  altered  balance  between  hemostatic  and
fibrinolytic  factors,  platelet  activation,  and altered  vascular  wall  growth.  Most  damage
occurs at  the level  of the cutaneous circulation and in  the microvasculature of various
internal organs. Small arteries and capillaries constrict, fibroproliferative changes in the
vasculature ensue later, eventually leading to obliteration of the vascular lumen, resulting
in ischemia. 
There are many potent mediators of tissue fibrosis that are believed to play an important
role in the pathogenesis of scleroderma. One of the key factors that has received the most
attention  as  a  very potent  profibrotic  factor,  indirectly  implicated  very strongly in  the
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pathogenesis of SSc, is transforming growth factor (TGF)-β1. A number of studies have
shown  that  TGF-β1  is  a  potent  profibrotic  factor  in  vitro  and  that  its  expression  is
upregulated in the skin and the lungs of Ssc patients. Other important growth factors are
connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF) and the
beta chemokines monocyte chemoattractant protein (MCP)-1 and MCP-3. 
Clinical manifestations.  Clinical manifestations of SSc are heterogeneous and vary as a
results of type of disease (limited or diffuse) and organ involvement (Table 1).
Table 1. Major clinical manifestations of SSc
Cutaneous
Diffuse edema of hands and feet (early stages)
Progressive skin tightening
Sclerodactyly
Calcinosis
Telangiectasias
Digital ulcers and pits
Contractures
Hyperpigmentation, hypopigmentation, salt and pepper skin
Characteristic facies
Vascular 
Raynaud's phenomenon
Nailfold capillary changes
Digital ischemia and ulcers
Vasculitic leg ulcers (rare)
Pulmonary 
Interstitial lung disease, including alveolitis and interstitial fibrosis
Pulmonary hypertension
Recurrent aspiration pneumonitis caused by esophageal reflux and dysmotility
Chest wall restriction (decreased thoracic compliance)
Respiratory muscle weakness
Cardiac 
Cardiomyopathy (systolic and diastolic dysfunction): 
       Congestive heart failure
Conduction defects:
        Septal infarction pattern
        Ventricular conduction abnormalities
        Arrhythmias
        Heart blocks
Pericarditis or pericardial effusion (impending renal crisis)
Renal 
        Scleroderma renal crisis (hypertension, renal failure, microangiopathic hemolytic anemia)
Musculoskeletal and Rheumatologic 
    Arthralgia
    Tendon friction rubs (relatively specific for diffuse scleroderma)
    Inflammatory arthritis, erosive arthropathy (rare)
    Myopathy, myositis
Gastrointestinal 
      Gastroesophageal reflux
      Esophageal dysmotility, aperistaltic esophagus
      Esophageal stricture
      Adenocarcinoma arising in Barrett's esophagus (occasionally)
      Watermelon stomach (gastric antral vascular ectasias [GAVE]): Iron-deficiency anemia
      Decreased peristalsis throughout the GI tract, leading to bloating, early satiety, stasis, and pseudo-obstruction
      Bacterial overgrowth and malabsorptive diarrhea, alternating diarrhea and constipation
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      Megacolon (rare)
      Colonic wide-mouth diverticuli (usually asymptomatic)
      Pneumatosis cystoides intestinales
      Primary biliary cirrhosis
      Anal incontinence
Endocrine
       Hypothyroidism
Neurologic
       Carpal tunnel syndrome
       Trigeminal neuralgia
Diagnosis.  Diagnostic  criteria  have  been  proposed  by  the  American  College  of
Rheumatology [28].
Table 2. American College of Rheumatology Diagnostic Criteria for Systemic Sclerosis
Major Criterion
     Proximal sclerodermatous skin changes (proximal to the metacarpophalangeal joints)
Minor Criteria*
Sclerodactyly
Digital pitting scars of fingertips or loss of substance of the distal finger pads Bibasilar 
pulmonary fibrosis
   * The patient should fulfill the major criterion or two of the three minor criteria.
A complete blood count, complete metabolic panel, muscle enzymes, thyroid function test,
and urinalysis  are  indicated in  all  patients.  Serologic  testing  for  autoantibodies  can  be
helpful in diagnosing and classifying SSc. However none of the serologic tests is sensitive
enough to independently exclude disease. Antinuclear antibodies (antitopoisomerase-I and
anticentromere  antibodies)  are  present  in  the  sera  of  more  than  95%  of  scleroderma
patients,  with  certain  clinical  phenotypes  associated  with  specific  ANAs.
Antitopoisomerase-I  antibodies  (anti-topo-I  or  anti-Scl-70)  are  100%  specific  for
scleroderma  and  are  present  in  30%  of  patients  with  the  diffuse  cutaneous  form.
Anticentromere (ACA) antobodies are highly specific for Ssc and are particularly common
in patients with the subset of limited SSc. Antinucleolar antibodies have been reported in
15% to 40% of patients with SSc [24]. 
Therapy. Although no therapy is proved to reverse the vascular and fibrotic damage in
patients  with  SSc,  several  therapies  are  available  in  an  effort  to  slow  down  disease
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progression,  improve  vascular  function,  limit  mortality  and  provide  supportive
symptomatic  care.  Patients  with  Raynaud's  phenomenon  are  advised  to  stop  smoking,
avoid  cold  exposure,  wear  warm  clothing  and  gloves,  and  avoid  vasoconstrictive
substances (clonidine, sympathomimetics, cocaine, ergot alkaloids). 
Various  pharmacologic  agents  are  aimed  at  reversing  digital  vasospasm.  The
dihydropyridine calcium channels blockers  (amlodipine and long-acting preparations of
nifedipine)  are  first-line  agents  for  the  treatment  of  scleroderma-associated  Raynaud's
phenomenon. 
The role of antiplatelet and anticoagulant therapy is unclear, although in the absence of
controindications,  most  experts  would  recommend  low  dose  aspirin  to  patients  with
Raynaud's phenomenon. 
Phosphodiesterase-5 (PDE5)  inhibitors  like sildenafil,  tadalafil  or vardenafil,  have been
found to be particularly useful in ameliorating refractory digital ischemia and ulceration,
presumably because of their vasodilative properties, although they have not yet received
regulatory approval for this indication [29]. 
Endothelin receptors antagonists (such as bosentan) are proved effective for the prevention
of ischemic digital ulcers [30,31]. 
Intravenous prostanoids (e.g. Epoprostenol, alprostadil, or iloprost) have also been shown
to ameliorate severe digital ischemia and improve digital ulceration [30]. 
Cyclophosphamide may be beneficial in patients with interstitial lung disease associated
with SSc. Multiple uncontrolled studies had suggested that cyclophosphamide might slow
the  loss  of,  or  even improve,  lung function  (specifically  FVC) in  the  setting  of  early
scleroderma with declining FVC and progressive dyspnea [32]. 
Methotrexate has been shown to improve skin scores, but the effects were modest [33].
Corticosteroids may be useful in the treatment of myositis and alveolitis, but their use is
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limited by the observation that high doses can precipitate renal crisis. 
Immunoablation  combined  with  autologous  stem  cell  rescue  is  still  considered
experimental, but one report documented improved skin scores. However 1-year mortality
was high after transplantation [34]. 
Angiotensin-converting enzyme inhibitors should be used at the first sign of renal crisis
(severe hypertension, renal failure, and microangiopathic hemolytic anemia). Their early
use  is  critical  in  preserving  renal  function,  controlling  hypertension,  and  improving
survival during renal crisis. In the hope that control of renin-mediated hypertension can
result in renal recovery, therapy with angiotensin-converting enzyme inhibitors should be
continued even in the face of renal insufficiency requiring dialysis [35]. 
Future directions: the central role of TGF-β in inducing endothelial damage and fibroblast
activation  has  led  investigators  to  target  this  molecule  as  a  promising  site  for  future
therapies.  Indeed,  anti-TGF-β  drugs  and  others  cytokine-based  therapies  could
theoretically provide true disease modification, especially in patients with early disease,
before cutaneous and internal fibroses result in significant irreversible damage [36]. 
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PULMONARY ARTERIAL HYPERTENSION 
IN SYSTEMIC SCLEROSIS
Pathogenesis of Pulmonary Arterial Hypertension in Systemic Sclerosis (SSc-PAH)
The pathogenesis and physiopathology of SSc-PAH look like those of IPAH. They  share
the same pulmonary artery lesions. This findings suggest similarities in physiopathology,
that is the involvement of inflammation and immunitary system in both the types of PAH.
However it is likely that inflammatory pathways and autoimmunity are more pronounced
in SSc-PAH, explaining clinical and prognosis differences between the two forms [37].
   Figure 1. Pathogenesis of pulmonary hypertension in SSc.
    EPC = endothelial precursor cells.
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      Figure 2. Pulmonary vascular remodeling in SSc-PAH.
      From: Le Pavec J et al. Systemic sclerosis-associated pulmonary arterial hypertension. 
       Am J Respir Crit Care Med 2010;181:1285-93.
Vascular changes occur at an early stage in SSc and include apoptosis, endothelial cell
activation  with  increased  expression  of  cell  adhesion  molecules,  inflammatory  cell
recruitment, a procoagulant state, intimal proliferation, and adventitial fibrosis leading to
vessel  obliteration.  Endothelial  injury  is  reflected  by  increased  levels  of  soluble  cell
adhesion  molecules,  disturbances  of  angiogenesis  as  reflected  by  increased  levels  of
circulating vascular  endothelial  growth factor, and presence of  angiostatic  factors  [38].
Thus,  the  role  of  dysregulated  angiogenesis  in  SSc-PAH,  whether  driven  by  the
inflammatory process or other mechanisms, is a predominant feature of the disease and
should be a focus of future studies as a potential target for therapy. The involvement of the
inflammatory cells is demonstrated by the finding of macrophages, T and B lymphocytes,
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and dendritic cells around plexiform lesions. Levels of macrophage inflammatory protein-
1a,  IL-1b  and  IL-6,  and  P-selectin  are  increased  in  severe  IPAH.  Involvement  of
leukocytes,  macrophages,  and lymphocytes,  initially described in  the complex vascular
lesions  of IPAH, is  also a  prominent feature in  PAH associated with connective tissue
diseases  [39].   A role  for  autoimmunity is  suggested  by the  presence  of  a  number  of
autoantibodies in the serum of patients with SSc.  Antibodies have also been reported in
SSc-PAH,  including  fibrin-bound  tissue  plasminogen  activator  in  patients  with  limited
cutaneous SSc, and in patients with IPAH with HLA-DQ7 antigen, and anti-topoisomerase
II-α antibodies, particularly in association with HLA-B35 antigen. In vitro, autoantibodies
from  patients  with  connective  tissue  diseases  (anti–U1-ribonucleoprotein  and  anti–ds-
DNA)  can  up-regulate  adhesion  molecules  and  histocompatibility  complex  class  II
molecules on human pulmonary arterial  endothelial  cells,  suggesting that inflammation
could  lead  to  pulmonary  proliferative  vasculopathy  [40].  Fibroblasts  are  found  in  the
remodeled  neointimal  layer  in  both  SSc-PAH  and  IPAH.  Thus,  the  detection  of  anti-
fibroblast  antibodies  in  the serum of  patients  with SSc-PAH and IPAH has  significant
pathogenic  importance  because  these  anti-bodies  can  activate  fibroblasts  and  induce
collagen synthesis, potentially contributing directly to the remodeling process. They induce
a  proadhesive  and  proinflammatory  response  in  normal  fibroblasts,  and  have  distinct
reactivity  profiles  in  IPAH  and  SSc-PAH,  as  assessed  by  immunoblotting.  Several
fibroblast antigens recognized by serum IgG from patients with IPAH and SSc-PAH have
so far been identified, including proteins involved in regulation of cytoskeletal function,
cell contraction, cell and oxidative stress, cell energy metabolism, and other key cellular
pathways [41]. 
Despite  recent  advances  in  genetics  regarding  SSc,  little  is  known  about  genetic
involvement in SSc-PAH. Mutations in the gene coding for bone morphogenetic protein
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receptor 2 (a member of the transforming growth factor-b receptor family) have not been
detected  in  two  small  cohorts  of  SSc-PAH  [42].  Recently,  an  association  between  an
endoglin  gene  polymorphism  and  SSc-PAH  was  reported.  Endoglin,  a  homodimeric
membrane glycoprotein primarily present on human vascular endothelium, is part of the
transforming growth factor-b  receptor complex. Although endoglin mutations are known
causes of hereditary hemorrhagic telangiectasia and have been rarely identified in patients
with  PAH,  the  functional  significance  of  endoglin  polymorphism  in  patients  with  SSc
remains to be determined [43].
Prevalence and incidence of SSc-PAH
In prospective studies using right heart catheterization (RHC) for diagnosis, the prevalence
of SSc-PAH is between 7.8 and 12% [19,44,45]. With an estimated U.S. prevalence of SSc
of about 240 cases per million and a conservative PAH prevalence of 10% among these
patients, the estimated overall prevalence of SSc-PAH is around 24 individuals per million,
which represents 5 to 10 times the number of patients affected by IPAH [46]. In the French
PAH registry, connective tissue disease (mainly represented by SSc) accounts for 15.3% of
PAH cases [5]. Probably because of a higher prevalence of SSc in the United States [47],
the proportion of SSc-PAH is at least 30% of patients with PAH, as indicated by one single
large registry [48]. In a recent prospective study, the estimated incidence of PAH among
patients with SSc was 0.61 cases per 100 patient-years [49].
However the hystopathological evidence of pulmonary arteriopathy was documented in
more  than  72%  of  SSc  patients,  suggesting  some  discrepancies  between  clinical  and
pathological data [50]. Prevalence of SSc-PAH based on echocardiographic diagnosis is
often overestimated; a survey conducted by 59 Societies of Rheumatology, on a population
of 909 subjetcs showed a prevalence of PAH in 27% of patients affected by SSc or other
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CTD, defining PAH on the basis of a PAsP value > 40 mmHg [51]. 
Several clinical markers are associated with an increased risk of developing PAH in the
setting of SSc, including limited skin involvement [52-55], disease duration greater than 10
years [53], late age of onset of Ssc [56,57], severity or duration of Raynaud's phenomenon,
and reduced nailfold  capillary density [53].  Several  investigators  have  emphasized  the
pivotal role of an isolated reduction in diffusing capacity of carbon monoxide (DLCO) or a
progressive decline of DLCO as an independent predictor for subsequent PAH [52,54].
Although the decrease in DLCO is likely the result  of progressive pulmonary vascular
remodeling over  time,  it  is  interesting to  note that  this  alteration is  significantly more
pronounced  in  patients  with  SSc-PAH  compared  with  IPAH  patients  [37],  perhaps
suggesting more profound small-vessel remodeling in the former compared with the latter.
Diagnosis of Pulmonary Arterial Hypertension in SSc [58]
As  previously  mentioned  some  risk  factors  are  associated  to  an  increased  risk  for
developing PAH in the setting of SSc:  limited skin involvement, disease duration greater
than 10 years,  late age of onset of SSc, severity or duration of Raynaud phenomenon,
reduced nailfold capillary density, but also positivity of anticentromere antibodies [59], the
presence of aninucleolar antibodies, anti U3 RNP and anti Th/To antibodies [60], increased
levels of BNP or NT-proBNP, and altered spirometric parameters that are DLCO < 60%, in
absence of diffuse interstitial lung disease or FVC%/DLCO% ratio > 1,6.
Many studies have highlighted the pivotal role of a reduced DLCO < 50% of the predicted
value  or  a  progressive  reduction  of  DLCO  as  an  indipendent  predictor  of  PAH
development [49], because DLCO could be significantly reduced many years before the
diagnosis of PAH [61].
The presence of dyspnea could activate a diagnostic work-up to define the presence of
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PAH, especially in those patients with reduced DLCO. In fact the risk of a late diagnosis or
a  misdiagnosis  remains  high,  because  of  slowly  development  of  dyspnea,  frequently
accounted for the presence of musculoskeletal manifestations or because of the reduction
of symptoms due to limitation in activity [62].
Fisher and colleagues underlined the need of an yearly echocardiographic screening in
patients  with SSc,  including the asymptomatic  ones,  to  avoid a  late  diagnosis,  usually
made after 2 or 3 years from the onset of the disease [60,63].  
Asymptomatic patients with normal functional respiratory tests (DLCO and FVC), could
also undergo echocardiographic study every 2 years. 
On the other hand, Campo et al. suggested the diagnostic work-up for PAH immediately
after the appearance of one of the symptoms referable to the underlying disease (except for
the Raynaud's phenomenon) [64].  
Table 1. Findings associated with PAH in SSc.
Symptoms Recent onset of dyspnea on exertion
Physical examination Signs of right heart failure
Echocardiographic findings TR jet > 3.0 m/s (PAsP > 40 mmHg)
Right ventricular dilatation/hypokinesis
Pericardial effusion
PFT DLCO% < 60% without significant pulmonary lung disease
FVC%/DLCO% >1.6
Other parameters Increased levels of BNP or pro-NT-BNP 
Reduced oxygen saturation during eexercise
     PFT: pulmonary functional tests.
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 Figure 3. Algorithm fot the diagnosis of lung disease in SSc. 
  ABG, arterial blood gas; ACL, anticardiolipin Ab; CTEPD, chronic thromboembolic pulmonary disease; 
  LAC, lupus anticoagulant; IAP, pulmonary arterial hypertension; PFT, pulmonary function tests; RHC, 
  right heart catheter; SPAP, systolic pulmonary artery pressure; TOE, transoesophageal echocardiogram; 
  V/Q   scan, ventilation/perfusion scan.
  From: Proudman SM et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early 
  detection  and treatment. Intern Med J 2007;37(7):485-94.
Biohumoral markers and evaluation of disease severity
Over  the  past  few  years,  the  Brain  Natriuretic  Peptide  (BNP)  and  its  precursor,  NT-
proBNP,  have been studied in various forms of PAH and found to be useful as prognostic
indicators in SSc-PAH and to assess the efficacy of the therapies [65].
BNP is released by the ventricular myocardium in response to volume or pressure overload
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and represents a marker of ventricular stretching; it was demonstrated that levels of BNP
correlate  with  functional  capacity,  mortality  and  right  ventricular  systolic  dysfunction.
Recent studies have also demonstrated that BNP and NT-proBNP could be useful in the
early diagnosis of PAH in patients at risk, such as those affected by SSc [66,67]. 
A NT-proBNP cut-off value of 365 pg/ml has been proven to have a sensitivity of 56-69%
and a specificity of 95-100% to identify the presence of PAH in SSc patients [65]. Mathai
et  al.  showed  that  SSc-PAH  patients  had  significanly  higher  levels  of  NT-proBNP
compared to IPAH patients, despite similar hemodynamic conditions. In SSc-PAH patients,
in addition to cardiac wall  stretching, another trigger mechanism for the production of
natriuretic peptides seems to be a more pronounced neuro-hormonal activation [68]. 
Combining the elevated levels of NT-proBNP with the reduced values of DLCO it could be
possible to obtain useful informations for the diagnosis and the follow-up of patients with
SSc-PAH [69].
A novel biomarker that could identify patients affected by IPAH or SSc-PAH is the Growth
differentiation factor 15 (GDF-15), that is a protein belonging to the transforming growth
factor beta superfamily that has a role in regulating cellular growth, differentiation, cell-to
cell signaling and apoptotic pathways. Probably it is also involved in the pathogenesis of
PAH. Recent data showed that SSc-PAH patients had increased levels of GDF-15 [70];
these levels directly correlate with pulmonary artery pressure and with FVC/DLCO ratio,
and are associated with a poor prognosis. 
Survival
SSc-PAH has emerged as a leading cause of mortality [71]. Before the introduction of the
new therapies, 5-year survival in patients with SSc-PAH was 10%, differently from the
80% survival of SSc patients without PAH [60].
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Compared with IPAH patients, those with SSc-PAH are almost four times more likely to
die from their disease [37,72]. Moreover, outcomes in SSc-PAH remain worse than those
in PAH associated with other CTD [73]. At a time of broader treatment availability, and
despite substantial improvements in other PAH categories, 3-year survival remains less 
       From: Le Pavec et al. Systemic sclerosis-associated pulmonary arterial hypertension. 
       Am J Respir Crit Care Med 2010;181:1285-93
than 60% (Figure 4) [73,74,37,49,19,75].
Markers of worse prognosis include male sex, late age at diagnosis, pericardial effusion,
functional  severity  based  on New York Heart  Association  functional  class,  right  heart
dysfunction, and hyponatremia [19,37,73,76].
Moreover patients with SSc-PAH have a more severe right ventricular dysfunction than
patients affected by IPAH, although it is unclear if this datum can explain the increased
mortality rate of SSc patients [77].
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Figure 4
(21) (37)
Pulmonary involvement in Systemic Sclerosis
Involvement of the lungs is present in about 60-70% of SSc patients, represents the leading
cause of mortality and morbidity [50] and consists most often of interstitial fibrosis or
interstitial lung disease (ILD) and pulmonary vascular disease leading to PAH. Autoptic
examinations showed lung fibrosis in the majority of SSc patients [71]. 
There are also patients that develop both PAH and ILD, as two distinct and indipendent
processes. Patients with limited SSc will tipically develop isolated PAH 10 to 15 years
after the onset of their disease, whereas patients with diffuse SSc are at greater risk for ILD
(occuring in the 75% of cases), usually within the first 5 years after diagnosis. In these
patients  fibrosis  can  cause  pulmonary hypertension  (PH-ILD).  PH is  generally  modest
(mean pulmonary arterial pressure: 25-35 mmHg), but in some patients, particularly those
with  only  moderate  pulmonary  function  impairment,  PAP  elevations  can  be  more
substantial (mean PAP: 35-50 mmHg). In this case PH is considered out of proportion to
the degree of lung impairment. However, although SSc patients with ILD alone have a
mean survival of 5 to 8 years, development of PH will significantly shorten survival. 
Recent studies have concluded that PH-ILD was associated with a fivefold increased risk
of  death  compared  with  SSc-PAH  [73].  When  dyspnea  occurs  in  SSc  patients  it  is
necessary to make the differential diagnosis between ILD, PAH, or other causes.  
Respiratory functional tests,  particularly DLCO, as already asserted,  represent  an early
marker of ILD and PAH and correlate with the severity of the underlying disease in both
cases  [78].  An isolated  reduction  of  DLCO is  observed  in  20% of  SSc  patients  [79].
Pulmonary fibrosis causes more specifically the reduction of respiratory volumes, and so
the total pulmonary capacity and the forced vital capacity (FVC). It has been proposed that
pulmonary disease severity in SSc was defined as mild, moderate or severe when values of
FVC and DLCO were 70-79, 50-69 and < 50% of predicted, respectively [80].  
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High resolution computed tomography (HRCT) permits to establish the severity grades of
ILD, considering the extent,  the localization of  the fibrosis,  the extent  of the reticular
pattern, and of the ground-glass opacities. HRCT has also a key role in the prognosis of
SSc patients [81]. A study enrolling 215 subjects, patients with more extensive pulmonary
fibrosis seen at HRCT (abnormalities involving > 20% of the pulmonary volume) have a
greater mortality and more progression of the lung disease than patients with pulmonary
involvement < 20%. HRCT has a high sensitivity to detect zones of fibrosis that have been
found  in  55-65%  of  SSc  patients,  up  to  96%  of  patients  with  abnormal  functional
respiratory tests [82].   
The risk of lung cancer is increased in patients with both limited or diffuse cutaneous SSc.
The incidence rate of malignant lung neoplasms is approximately fivefold higher than that
for an age and gender matched subset of the general population. 
Cardiac involvement 
Heart  involvement  in  SSc patients  is  either  primary,  related  to  myocardial  fibrosis,  or
secondary, as may occur in cases complicated by PAH or systemic hypertension in those
with renal crisis. Primary involvement can exhibit as myocardial dysfunction, conduction
defects, arrhythmias and pericardial disease. 
Clinically evident cardiac involvement is present in less than 25% of the subjects, although
80% of  SSc patients  have  cardiac abnormalities  seen at  autopsy [83].  The responsible
mechanisms are: microvascular injury, interstitial fibrosis, pulmonary hypertension.  
Myocardial fibrosis is thought to result from recurrent vasospasm of small vessels and it is
often associated with contraction band necrosis, that is a histological lesion indicative of
myocardial ischemia folowed by reperfusion. The degree of myocardial fibrosis may be
increased in SSc patients with a long history of Raynaud's phenomenon. 
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Diastolic and systolic dysfunctions of both the right and left ventricles are common in SSc
patients [84]. Echocardiographic evaluation using tissue Doppler has a high sensitivity to
detect myocardial abnormalities, especially the diastolic dysfunction [85]. 
Cardiac RMN allows to identify the subclinical myocardial involvement in asymptomatic
SSc  patients,  showing  reduced  end-diastolic  and  end-systolic  ventricular  volumes
compared to healthy subjects  [86,87]. 
Cardiac RMN seems to have higher sensitivity than echocardiography (75% versus 48%),
because  its  ability  to  directly  visualize  the  presence  of  fibrosis  or  scar  using  late
gadolinium enhancement, signal intensity, and myocardial wall thinning [87]. 
The prevalence of atherosclerotic coronary artery disease is not higher in SSc patients than
the general population; they often have coronary microvascular dysfunction rather than
epicardial  coronaries  involvement.  Moreover  the  spasm of  small  coronary arteries  can
occur, termed myocardial Raynaud's phenomenon. 
Conduction system disease and arrhythmias are common. They are likely to result from
fibrosis of the myocardium and conduction system. Many death among SSc patients are
sudden, and some may result from ventricular arrhythmias. 
Symptomatic  pericarditis  occurs  in  7  to  20%  of  patients  with  SSc,  but  pathological
evidence  of  pericardial  involvement  is  observed  in  70  to  80% at  autopsy.  Pericardial
effusions may be small or large and can develop rapidly.
The role of echocardiography in Systemic Sclerosis
Echocardiography allows the evaluation of many cardiac complications of SSc. The main
role is the study of systolic and diastolic left  ventricular function,  the right ventricular
systolic function evaluation, the assessment of pericardial involvement and the estimate of
systolic pulmonary arterial pressure. 
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Left ventricular diastolic function. Diastolic function is often impaired in SSc patients, and
can present different grades of severity, coming from the impaired relaxation up to the
restrictive pattern; the study of diastolic function consists in a pluriparametric evaluation as
already previously described.  
Left ventricular systolic function. It is less often impaired than diastolic function. It could
be the manifestation of a primary cardiac damage or secondary to arterial hypertension or
renal crisis. Systolic dysfunction can be classically evaluated by the measurement of the
ejection fraction of the left ventricle, but recently other tecniques are available to detect
subclinical and early stages of systolic impairment. 
TDI:  Doppler  tecnique  permits  the  evaluation  of  myocardial  tissue  velocities;  the
measurement of  longitudinal systolic velocity S' of the left ventricular lateral wall, is an
index of the longitudinal contractile function of the left ventricle, that is a parameter of
early systolic dysfunction [84].  
Speckle-tracking: this tecnique is used for the measurement of myocardial strain that is the
percentage change in length of a myocardial segment respect to its initial lenght. It is an
index of myocardial wall deformation that was recently introduced in clinical practice [88],
and in SSc patients has been demonstrated to be a valid tecnique to detect subclinical
myocardial involvement [89]. 
Right  ventricular  systolic  function. SSc  patients  can  have  right  ventricluar  systolic
dysfunction  either  primary  or  secondary  to  pulmonary  hypertension.  The  routine
evaluation  of  the  systolic  function  of  the  right  ventricle  provides  the  measurement  of
TAPSE, TAV and right ventricle fractional area change, as already illustrated in a previous
chapter [90]. 
Pericardial diseases. Echocardiographic evaluation of the pericardial  layers help in the
diagnosis  of  pericardial  complications  that  are:  acute  pericarditis,  pericardial  effusion,
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pericardial tamponade  or constrictive pericarditis. 
Pulmonary hypertension. Echocardiography is the more used non-invasive tool for initial
diagnosis  of PAH, for the screening of high risk population,  for the evaluation during
follow-up, and for the assessment of prognosis and the efficacy of therapies.  
The echocardiographic estimate of systolic arterial pulmonary pressure and the other useful
parameters that integrate the study are already previously described. 
The PAsP values, assessed by ecocardiography, that indicate the diagnosis of PAH and
recommend the execution of RHC, are still not clear. Moreover PAsP estimate is never the
only parameter used to establish the need to further evaluations. In both the IPAH and the
SSc-PAH cardiac function, particularly the right ventricle function, represents one of the
most important predictors of survival, hence deserving a careful assessment, using also
new tecniques such as speckle tracking and strain measurement. 
Exercise echocardiography in Systemic Sclerosis 
Pulmonary  hypertension  induced  by  exercise  (mean  PAP  ≥  30  mmHg)  is  no  more
considered a diagnostic definition, because it is not supported by published data, and it
lacks standardised parameters concerning the type and level of exercise, that could affect
the value of the mean PAP. Moreover, in contrast to the PAP at rest, PAP during exercise is
largely age-dependent; younger healthy subjects aged < 50 years can reach values > 30
mmHg during submaximal or maximal exercise; after a mild exercise, 50% of subject over
fifty years of age can reach values > 30 mmHg [91,92].
In healthy subjects a moderate effort induces an increase of cardiac output and pulmonary
blood flow with a reduction of vascular resistance and only mild increase of pulmonary
pressures [91]. Neverthless in well-trained atlhletes, high levels of work are accompanied
by remarkable increase of cardiac output and increase of left  ventricular and left atrial
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pressures,  causing  higher  pulmonary  pressures  levels  [93].  Thus,  with  the  previous
definiton many individuals were incorrectly labelled as pulmonary hypertensive, that in
fact had simply a physiological exercise response. Taking into account all these variables,
it seems impossible to come up with a solid definition of PH during exercise. So in the
current guidelines it  was decided to abandon the exercise criterion.  Further research is
ongoing in this field to generate the data that are needed to move forward in this important
area of pulmonary vascular dissease. In the last years many works have focused on the use
of exercise echocardiography to study the pulmonary artery pressure during exercise. The
first symptom in PAH patients is often dyspnea on exertion, so the change in PAP with
exercise could provide a possible tool to detect a subclinical phase of pulmonary vascular
disease, that is an intermediate stage between resting pulmonary arterial hypertension and
normal [16]. 
Many studies have shown that exercise echocardiography could be a useful tool to make an
early diagnosis of pulmonary vascular disease in patients with SSc, to start appropriate
therapies in an early stage of the disease that coul be more efficacious, although long-term
results and prognostic value of such test remains unknown [94].  
Data about the prevalence of exercise pulmonary arterial hypertension are limited: Grunig
et  al.  in  2000  have  published  studies  involving  patients  carrying  genes  for  familial
pulmonary hypertension: in 48% of these subjects they found PAP values on exercise > 40
mmHg [95]. Collins et al. have studied 51 patients affected by autoimmune diseases and
have found exercise pulmonary arterial  hypertension in 59% of subjects,  considering a
PAsP cut-off of 35 mmHg [96]. 
Reichemberger and Callejas-Rubio using a PAsP cut-off value of 40 mmHg have found
exercise PAH in 45-50% of SSc patients [97,98]. Recent data have showed prevalence of
exercise PAH in 40% of SSc patients (defining the PAsP cut-off ≥ 50 mmHg) [99]. 
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Steen et  al.  studied  54 patients  affected  by SSc at  high  risk to  develop PAH because
presenting  dyspnea  on  exertion  or  abnormalities  on  functional  pulmonary  tests  or  on
echocardiogram (PAsP > 35 mmHg). These subjects underwent stress echocardiography
and the result of the test was considered positive when mean PAP increased at least 20
mmHg. Patients with positive result at stress echocardiography were submitted to right
heart catheterization that confirmed the presence of PAH in 81% of cases [100]. 
D'Alto and coworkers have compaired the values of PAsP during exercise in  172 SSc
patients with a control group and demonstrated that the first group had PAsP values higher
than the second group, especially in the presence of interstitial lung disease or diastolic
dysfunction.  Moreover the distribution of esercise PAsP was bimodal  and 13% of SSc
patients had exercise PASP values ≥ 48 mmHg [101]. 
Assuming that PAH induced by exercise could be an intermediate stage between normal
condition and rest PAH, the follow-up of such patients could be important, but in literature
there are few data. 
Condliffe  and his  group described 42 SSc patients with PAH induced by exercise and
found the progression toward rest PAH, after a mean period of 2,3 years, in 8 patients
(19% of cases), performing right heart catheterization; 4 out of these 8 patients (9,5%) died
as a consequence of pulmonary vascular disease within 3 years after the diagnosis [73]. 
More recently Codullo and coworkers studied a group of patients with altered pulmonary
response  to  exercise  diagnosed  by  stress  echocardiography  (PAsP  ≥ 48  mmHg)  and
confirmed  by  RHC;  patients  were  followed  for  about  3,5  years  and  3,5  %  of  cases
developed resting PAH [102]. In conclusion exercise echocardiography has still a role in
the research field because it is a complex tool that need a significant expertise and has not
yet an appropriate standardization, regarding the methods of execution and interpretation
of the test. However the potentialities of such tool, in a selected group of patients, could be
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enormous and should have necessarily still investigated. 
Right heart catheterization (RHC) is mandatory to make a definitive diagnosis of PAH;
SSc patients with dyspnea of unknown origin and the finding of a PAsP > 40 mmHg or
signs of right ventricular dysfunction should undergo RHC [60]. 
RHC should be considered also in patients with risk factors for the development of PAH
(limited cutaneous form of Ssc, Raynaud's phenomenon lasting > 8 years, positivity of
anti-centromere  antibodies,  isolated  positivity  of  anti-nucleolar  antibodies,  diffuse
teleangectasia), patients with low DLCO (< 60%), or FVC%/DLCO% ratio > 1,6, with
dyspnea of unknown origin and echocardiographic signs of right ventricular dysfunction.
During  RHC it  is  possible  to  perform the  pulmonary vasoreactivity tests,  although its
utility in SSc patients is uncertain. On the other hand only 1% of SSc patients have positive
results  at  pulmonary vasoreactivity tests,  and high doses  of  calcium channels  blockers
could be dangerous in SSc-PAH patients because their negative inotropic and hypotensive
effects [103].
Table 2. Decision algorithm fot screening and recommendation for RHC in SSc.
                Parameters Low risk Intermediaterisk
Moderate
risk High risk
 Dyspnea or
 Raynaud’s phenomenon  
lasting > 8 years
 Anti centromere or isolated 
anti nucleolar antibodies-ANA
yes yes yes
DLco (without emphysema or 
interstitial lung disease) > 70% > 70% < 70% < 60%
FVC%/DLco% <1.6 <1.6 >1.6 > 1.6
PAsP < 35 mmHg < 35 mmHg > 35 mmHg > 40 mmHg
Recommendations
Repeat PFT
every year,
and  echo
cardiogram
every
2-3 years
Repeat PFT
every year,
and echo
cardiogram
every year
Repeat echo
cardiogram
after 3-6
months or
perform right
heart catethe
risation
Perform right
heart catethe
risation
             PFT: pulmonary functional test.
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THERAPEUTIC OPTIONS IN PULMONARY ARTERIAL
HYPERTENSION 
Before the approval of the more recent drugs, the therapeutic options in PAH consisted of
the  use  of  supplemental  oxygen,  diuretics,  digoxin,  high  doses  of  calcium  channels
blockers  and  anticoagulation,  in  addition  to  an  adeguate  training  program to  improve
functional capacity.  Although the use of supplemental oxygen and anticoagulation have
contributed  to  improve  survival,  prognosis  remains  severe,  except  for  the  minority  of
patients with IPAH that respond to high doses calcium channels blockers therapy.  
Currently there are three main approaches to the pharmacological management of PAH,
which targets its underlying pathophysiology via the prostacyclin-, endothelin- and NO-
mediated pathways.  So the new available main therapeutic modalities are:  prostacyclin
analogs  (epoprostenol,  treprostinil,  iloprost),  endothelin  receptor  antagonists  (bosentan,
ambrisentan and sitaxsentan) and phosphodiesterase inhibitors (sildenafil, tadalafil) [104].
Prostacyclin analogs. Epoprostenol, a syntethic prostacyclin, is the first agent of this class
approved in 1995 for the treatment of PAH. It is a potent nonselective vasodilator and
antiproliferative agent and has a short half-life so it is given via continuous intravenous
infusion through a peripheral or central line. Epoprostenol have demostrated its efficacy in
improving  survival  in  IPAH  [105],  but  data  regarding  patients  with  SSc-PAH  are
insufficient. Menon et al. studied 7 patients with SSc-PAH demonstrating that treatment
with epoprostenol significantly reduced both mean PAP and pulmonary vascular resistance,
with simultaneous increase of cardiac output [106]. The works of Humbert,  Badesch e
Klings also confirmed the positive data regarding the use of epoprostenol in SSc-PAH
patients, but all the studies were performed in small group of patients [107-109].
Treprostinil  offers  the  option  of  subcutaneous  administration  and  improves  symptoms,
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exercise capacity and hemodynamics in connective tissue disease associated with PAH
[110]. 
Inhaled iloprost, has been approved in 2004 for the treatment of NYHA class III and IV
PAH patients and its action seems to be selective for pulmonary circulation [111].
Beraprost,  an  orally  administered  prostacyclin,  has  been  demonstrated  efficacious  in
improving DLCO in patients with  SSc-PAH [112]. 
Endothelin-receptors antagonists. PAH is  associated with excess  production of  ET-1,
therefore blocking the effects of ET-1 via antagonism of the ETA and ETB receptors, which
mediate its deleterious vasoconstrictive and mitogenic effects, is an important therapeutic
strategy. In 2002 bosentan, a dual receptor antagonist has been introduced in the treatment
of PAH. In two placebo-controlled trials, bosentan, orally administered, demonstrated its
efficacy in IPAH and SSc-PAH, improving functional capacity, hemodynamics, and time to
clinical worsening [113,114].  Generally this drug is well  tolerated,  but the typical side
effect is an increase of liver function tests, that occurs in about 10% of patients; these
hepatic effects could be managed with simple measures (treatment interruption or dose
reduction). 
Ambrisentan e Sitaxsentan, selective antagonists of ETA receptor has been introduced later,
but there are still not clear the advantages of such selective inhibition [115]. 
Phosphodiesterase  inhibitors.  Inhibition  of  phosphodiesterase  type-5  (PDE-5),  an
enzyme that rapidly degrades cGMP, limiting the NO-mediated pulmonary vasodilatation,
causes vasodilation and antiproliferative actions, especially in the pulmonary vascular bed
where it is well represented. Sildenafil, taldalafil and vardenafil, has been approved for use
in PAH, including SSc-PAH) [116].
Combination therapy.  Given that currently available therapies target different pathways
implicated  in  the  pathophysiology  of  PAH,  there  is  a  strong  rationale  for  combining
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different therapies with the aim of optimizing treatment response. This can be achieved by
either  the  simultaneous  administration  of  two  or  more  targeted  treatments  or  by  the
sequential addition of one or more agents to ongoing therapy. A metanalysis conducted by
Galiè and coworkes in 2009, including all the randomized studies performed from 1990 to
2008, regarding the treatment with the new therapies, demonstrated an improvement in
survival in these patients [117]. Nowadays combination therapies have become common
practice and many multicenter studies have evaluated the efficacy of various combination
of oral, endovenous or inhalated agents [118].  
Immunosuppresive therapy. Recently, investigators have been evaluating the ability of
antineoplastic  agents  to  slow  aberrant  proliferation  of  vascular  smooth  muscle  and
endothelium in  PAH.  Imatinib  mesylate  is  a  tyrosine  kinase  inhibitor  used  in  chronic
myelogenous  leukemia.  Initial  reports  have  shown  improvement  in  PVR  and  cardiac
output  in  PAH patients  [119].  Rituximab,  an  anti-CD20 medication  that  targets  B-cell
populations and may lower platelet-derived growth factor-specific antobodies, is also being
studied within a SSc-PAH population as a result of case reports of improved outcomes in
patients with advanced stage [120].
Surgical therapy. Atrial septostomy may provide temporary symptomatic relief in patients
who have not responded to other therapies. By creating a right-to-left intraatrial shunt, the
intention of atrial septostomy is to decrease right ventricular filling pressures to improve
cardiac  output  and  overall  systemic  oxygen  delivery.  The  long-term benefits  of  atrial
septostomy remain  unclear  because  these  data  often  are  skewed  by  the  fact  that  the
procedure is usually used as a bridge to transplant or as a palliative measure [7]. 
Lung transplantation is a therapy of last resort for many patients. Unfortunately patients
with  SSc are  generally  considered  poor  candidates  for  lung transplantation  because  of
multi-organ disease or esophageal dysmotility, which may increase the risk of aspiration.
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Nonetheless, carefully selected patients may tolerate transplant well [121].
Treatment algorithm.  The suggested initial approach after the diagnosis of PAH is the
adoption of the general measures, the initiation of the supportive therapy and referral to an
expert center. Acute vasoreactivity test remains mandatory in all patients with PAH (group
1),  although  patients  with  idiopathic  PAH,  heritable  PAH,  and  PAH  associated  with
anorexigen use are the most likely to exhibit an acute positive response and to beneft from
long-term  therapy  with  calcium  channels  blockers  (CCB).  CCB  should  be  started  at
maximal tolerated doses and an adeguate response should be confirmed after 3 to 4 months
of treatment. Patients with a negative vasoreactive test and with NYHA functional class II
should be treated with an endothelin-receptor antagonist or a PDE-5 inhibitor. 
NYHA  functional  class  III  patients  should  be  treated  with  an  endothelin-receptor
antagonist or a PDE-5 inhibitor, or a prostanoid.
As  head-to-head  comparisons  among  different  agents  are  not  available,  there  is  no
evidence-based first-line  treatment  for  either  NYHA functional  class  II  or  III  patients.
Intravenous  administration  of  epoprostenol  is  recommended  as  first-line  therapy  for
NYHA class IV patients; in case of inadeguate clinical response sequential combination
therapy should be considered: association of an endothelin-receptor antagonist  and/or a
PDE-5 inhibitor or a prostanoid (double or triple therapy).
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             Figure 6. Evidence-based treatment algorithm.
   APAH: associated pulmonary arterial hypertension; BAS: balloon atrial septostomy; 
                 CCB: calcium channel blockers; ERA: endothelin receptor antagonist; 
                 sGCS: soluble guanylate cyclase stimulators; IPAH: idiopathic pulmonary arterial hypertension; 
                 i.v.: intravenous; PDE-5i: phosphodiesterase type 5 inhibitor; s.c.: subcutaneous; 
                 WHO-FC: World Health Organization functional class. 
                 From: Galiè N et al. Guidelines for the diagnosis and treatment of 
                             pulmonary arterial hypertension. Eur Heart J 2009;30:2497-2537.
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AIM OF THE STUDY
The aim of our study was to evaluate, using exercise echocardiography, the prevalence of
exercise-induced  abnormal  pulmonary  vascular  reactivity,  in  asymptomatic  or  mildly
symptomatic  patients  affected  by  systemic  sclerosis,  with  normal  pulmonary  artery
pressure at rest. We also measured values of BNP both at rest and during exercise test.
During exercise echocardiography we estimated pulmonary artery systolic pressure, and
we correlated  these  values  with  clinical,  echocardiographic  and  functional  parameters.
Moreover the results of BNP measurement, at rest and during exercise, were correlated
with exercise PAsP values. After a medium-long term follow-up (mean observation period
of  5,1 ± 0,4 years) we evaluated patients with a clinical assessment and we performed a
rest echocardiography to detect the development of resting PAH, assessing the predictive
value of exercise echocardiography for early identify patients at risk to develop PAH.
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MATERIALS AND METHODS
Study population
We  enrolled  40  consecutive  patients  affected  by  Systemic  Sclerosis  referred  to  our
Echocardiography  laboratory  (Cardiology  Unit  of  Camposampiero  Hospital,  Padua)
between January 2009 and December 2009, coming from the Rheumatology Unit of the
University  of  Padua.  Diagnosis  of  SSc  was  based  on  the  American  College  of
Rheumatology criteria [28].
Exclusion  criteria  were  the  following:  1)  patients  older  than  70  years,  2)  atrial
fibrillation/flutter,  3)  post-capillary diastolic  dysfunction,  4)  PAH at  rest,  5)  deep vein
thrombosis history or vascular doppler echo positivity of the lower limbs, 6) inability to
perform an exercise stress test because of comorbidity or poor compliance. 
The protocol of this study was approved by the ethic committee of the Hospital, and the
partecipants gave written informed consent.
Patients were evaluated on the basis of the age, gender, time to diagnosis, type of SSc
(diffuse  cutaneous  or  limited  cutaneous  form),  autoantibody  subset  (anti-centromere,
antiScl-70  and  nonspecific  ANA antibodies),  WHO/NYHA functional  class,  associated
diseases, cardiovascular risk factors, family history of autoimmune diseases, diagnostic test
as  spirometry  with  DLCO,  and  high  resolution  computed  tomography  (HRCT),  and
ongoing treatment.
At the time of the study many patients were treated with oral vasodilators (25) and with
anti-ulcer agents; moreover 6 patients received immunosuppressive therapy for SSc (3 with
azathioprine, 1 with methorexate, 1 with cyclosporin and 1 with mofetil mycophenolate). 
Spirometry test  consisted  of  measurement  of  TLCO/VA [diffusing  capacity  for  carbon
monoxide corrected for alveolar volume in maximal inspiration (ml/min/mmHg/L)] and
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FVC  (forced vital capacity) assuming that values > 100% in males and > 85% in females
exclude restrictive lung disease [122]. Matching the values of TLCO/VA and FVC and
findings of the HRCT we established a grading of the interstitial lung disease to identify
the effect of the lung disease on the parameters evaluated in our study:
• grade 0: absence of interstitial lung disease 
• grade 1:  mild interstitial lung disease 
• grade 2: moderate interstitial lung disease 
• grade 3: severe interstitial lung disease 
During follow-up many clinical parameters were considered: symptoms, functional class,
treatment changes, new onset of cardiac or extracardiac diseases or new cardiovascular risk
factors.
Resting echocardiographic study
All  patients  previously  underwent  a  comprehensive  rest  transthoracic  echocardiogram
using IE33 ultrasound machine (Philips medical Systems, Andover, MA), equipped with
2.5- to 3.5-MHz fased-array transducers, second harmonic technology, and coupled with
tissue Doppler imaging (TDI). The following parameters were assessed: walls thickness
and diameters of the cardiac chambers measured in parasternal long axis view using B-
mode technique.  Volumes of the left  ventricle and the ejection fraction were measured
from apical  4-chambers  view using  Simpson  method.  Diastolic  function  was  assessed
through the following parameters: Doppler velocities of the E and A waves of transmitral
flow and E/A ratio, the deceleration time (DT) of the E wave, measurement of E' and A'
diastolic  velocities  of  the  lateral  mitral  annulus  using  tissue  Doppler,  and  Doppler
velocities  of  the  systolic  (S)  and diastolic  (D) pulmonary venous flow from apical  4-
chambers view. Right ventricular function was detected by the measurement of TAPSE
(tricuspid annular  plane  systolic  excursion)  and TAV (tricuspid annular  velocity)  using
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respectively M-mode and TDI tecnique. End-diastolic, end-systolic areas and the fractional
area change (FAC) of the right ventricle have also been assessed. The systolic pulmonary
arterial pressure (PAsP) was derived from the maximal velocity of tricuspid regurgitant jet
according to the simplified Bernoulli equation and adding right atrial pressure, estimated
from  the  dimension  and  collapsibility  of  the  inferior  vena  cava.  The  end-diastolic
pulmonary pressure  (dPAP) was obtained using Bernoulli formula, from the velocity of
pulmonary regurgitant jet and adding right atrial pressure; such echocardiographic estimate
of dPAP is significantly correlated to dPAP measured by RHC [123]. We also measured the
acceleration time (AT) of the pulmonary artery flow, that is inversely correlated to PAsP
and to mean PAP [124,125]. 
During  the  echocardiographic  study  systemic  arterial  pressure,  heart  rate,  oxygen
saturation and measurement of BNP blood levels at rest were also assessed. 
At follow-up we performed echocardiographic study evaluating the parameters previously
described,  and  in  particular  we  estimated  the  pulmonary  artery  systolic  pressure  to
recognize the development of PAH. 
Exercise Echocardiographic study 
Exercise stress echo was conducted using a Ergoline graded semisupine bycicle ergometer
with 25-W incremental loading every 3 minutes. A 12-lead electrocardiogram and blood
pressure and oxygen sauration measurement were performed at baseline and every minute
thereafter.  Transthoracic  2-dimensional  echocardiographic  monitoring  was  performed
throughout and up to 5 minutes after the end of stress, mostly using the apical 4-chamber
view. Every step we measured volumes, and ejection fraction of the left ventricle, diastolic
function  using  pulmonary  venous  flow  and  E/e'  ratio  and  pulmonary  systolic  arterial
pressure. Moreover measurement of BNP blood levels was performed at peak exercise.
Resting pulmonary artery hypertension was defined by PAsP values > 40 mmHg (referring
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to tricuspid regurgitant velocity > 3m/sec plus right atrial pressure of 5 mmHg) [101]. A
cutoff value of PAsP ≥ 48 mmHg at peak exercise was considered a significant exercise-
induced increase in PAsP [99].
Analysis  of the diastolic filling of the left  ventricle allows to distinguish between pre-
capillary forms of PH (with normal left ventricle filling pressure) and post-capillary form
(with increased left ventricle filling pressure). During exercise echocardiography it is more
reliable to detect pulmonary venosu flow and E/e' ratio as indices of diastolic function;
actually E and A waves analysis, E/A ratio and deceleration time of the E wave could be
difficult to estimate during effort for the frequent fusion of the doppler waves due to the
high heart rate and for the presence of artifacts due to the polypnea.  
BNP
All patients had two blood samples  collected for BNP measurement  from the antecubital
vein at the time of the clinical and echocardiograpic assessment: the first withdrawal was
made in the supine position after a rest of at least 20 minutes, the second at peak of the
exercise. The blood was stored in a 10 ml test tube containing ethylenediamine tetraacetic
acid and no later than 10 minutes we measured BNP levels  by Triage BNP test (Biosite,
USA), that is a rapid immunofluorometric assay allowing BNP determination ranging from
5 pg/ml to 5,000 pg/ml, with a known cut-off value for heart failure of 100 pg /ml.
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STATISTICAL  ANALYSIS
The results are expressed as mean ± standard deviation for quantitative variables and as
absolute and relative frequencies for qualitative variables.  The comparison between SSc
patients who  developed exercise  PAH and  those who  did  not was  performed using
Student's t test. In the event that the applicable conditions were not met, we performed the
Mann-Whitney test.  The  qualitative  variables between  the  two groups were  compared
using the Chi-square or Fisher's test. Pearson's linear correlation coefficient (r) and simple
linear regression were used for correlations between exercise PAH and the other variables.
Concerning data obtained at follow-up, clinical and echocardiographic parameters of the
group of patients who developed resting PAH were compared to the remaining patients
population  and  also  to  the  patients  group  with  exercise  altered  pulmonary  artery
vasoreactivity, using Wilcoxon test.
All analyses were performed using a value of P <0,05 as significant  and using the Stata
software version 11.0.
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RESULTS
40 patients with SSc were recruited in the study (7 males and 33 females, mean age 52.2
years ± 9.8),  21 out of them with limited sclerosis (52.5%) and 19 with diffuse sclerosis
(47.5%).  The  clinical  characteristics  of  the  patients  are  presented  in  Table  1.  The
echocardiographic study showed that the average PAsP at rest was 26.5±4.6 mmHg and
reached a value of 45.1±14.2 mmHg with exercise with an average increase of 18.7±11.9
mmHg.  Assuming  the  PAsP cut-off  value  ≥ 48  mmHg to  define  the  exercise-induced
pulmonary hypertension, we divided the population into two groups: group A (25 patients,
62,5%) = normal pulmonary artery vasoreactivity (with PAsP < 48 mmHg) and group B
(15 patients, 37,5%) = altered pulmonary artery vasoreactivity (with PASP  ≥ 48 mmHg).
The two groups were compared in terms of clinical, echocardiographic, hemodynamic and
functional data as shown in table 1, 2 and 3.
Regarding the clinical data the patients enrolled in our study were predominantly females
(82,5%),  and  all  patients  belonging  to  group  B  were  females,  resulting  a  significant
difference in terms of sex between the two groups (p 0,03). In addition, group B patients
were older (56 ± 10,3 years) than group A patients (50 ± 9,1 years), but the difference was
not statistically significant. In addition, female patients were aged more than 10 years than
male patients (p 0,0319). We didn't find any statistically significant difference between the
two  groups  regarding  the  subsets  of  disease  (diffuse  cutaneous  and  limited  cutaneous
forms), the autoantibodies subset, and the disease duration.
Regarding  pulmonary  functional  tests  we  didn't  find  any  significant  difference  of
TLCO/VA, FVC and grade of interstitial lung disease, although group B patients had lower
TLCO/VA values (62,9 ± 21,4) than group A patients (72,9 ± 21%). Similarly there was no
difference between the two groups regarding NYHA functional class, but 60% of patients
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with  NYHA functional  class  I  belonged to  group A and 46% of  patients  with  NYHA
functional  class  II  belonged  to  group  B.  All  patients  affected  to  systemic  arterial
hypertension (n = 3) were in  group A. With regard to drug therapy, the datum did not
significantly correlate to the development of altered pulmonary vascular responsiveness.
Table 1. Clinical parameters of the study population, divided according to the pulmonary
vascular response to stress.
Clinical parameters    Patients       Subgroup with
impaired vascular
reactivity       
Subgroup with
normal vascular
reactivity
P value
Number (%) N= 40 (100%) N= 25 (62,5%) N= 15 (37,5%)
Males   (n, %)        7 (17,5%) 7 (28%)    0 (0%) 0,03
Females (n, %) 33 (82,5%) 18 (72%)  15 (100%)
Age   (years)   52,2 ± 9,8      50 ± 9,1 56 ± 0,3 n.s.
Age (males, years) 45,9 ± 7,1 45,9 ± 7,1 - n.s.
Age (females, years) 53,6 ± 9,9 51,6 ± 9,4 56 ± 10,3 n.s.
Limited sclerosis (n, %)  21 (52,5%)    12 ( 48%) 9 (60%)
n.s.
Diffuse sclerosis (n, %) 19 (47,5%) 13 ( 52%) 6 (40%)
Length of the disease 
(years)                      8,75 ±5,87 9,04 ± 5,96 8,27 ± 5,89 n.s. 
Length of the disease          
(Limited form, years)        8,76 ±5,92 8,67 ± 5,28 8,89 ±7,01 n.s.
Length of the disease 
(Diffuse form, years) 8, 74 ± 5,98 9,38 ± 6,73 7,33 ± 4,08 n.s.
Antibody subset:
Scl-70 (n, %)                       
ACA (n, %)                         
Nonspecific pattern (n, %)
17 (42,5%)
   16 (40%)      
7 (17,5%)
12 (48%)
10 (40%)
3 (12%)
  5 (33,3%)
6 (40%)
  4 (26,7%)
n.s.
Functional class:
NYHA I    (n, %)           
NYHA II  (n, %)
23 ( 57,5%)
17 (42,5%)
15 (60%)
10 (40%)  
8 (53,3%)
7 (46,7%)
n.s.
n.s.
Systemic hypertension (n,
%) 3 (7,5%) 3 (12%) 0 (0%)
n.s.
BSA (m2) 1,69 ± 0,16 1,73   ± 0,17 1,63 ± 0,11 n.s.
Pulmonary functional test:
TLCO/VA (%) 69,1±21,4 72,9 ± 21 62,9 ± 21,4 n.s.
FVC (%) 98,7± 19,6 98,7±17,6 98,7±21 n.s.
Interstitial lung disease
Grade 0 (n, %)
Grade 1 (n, %)
Grade 2 (n, %)
Grade 3 (n, %)
  23 (57,5%)
12 (30%)
 5 (12,5%)
0 (0%)
15 (60%)
8 (32%)
2 (8%)
0 (0%)
8 (53,4%)
4 (26,6%)
3 (20%)
0 (0%)
n.s.
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Regarding the resting echocardiographic measurements (Table 2), thickening, volumes and
diastolic and systolic parameters of the left ventricle were normal, as data about the right
ventricle. Exercise echocardiography showed a reduction of left ventricular volumes and a
slight increase of the LV ejection fraction. Regarding diastolic function, during effort, E/e'
ratio and S/D ratio remained whithin the normal range. Comparing the two groups, we
found a significant difference regarding the PAsP at rest  (p 0.0077), the exercise PasP (p
0.000),  and  the  increase  of  the  PAsP  with  the  exercise  (p  0.000).  The  other
echocardiographic parameters didn't show significant differences between the two groups.
 
Table 2.  Echocardiographic parameters of the study population, divided according to the
pulmonary vascular response to stress.
Echocardiographic parameters Patients(N=40)
Subgroup with
normal vascular
reactivity   
(N=25) 
Subgroup
with impaired
vascular
reactivity  
(N=15)  
P value
mean sd mean sd mean sd
Left atrium (AP diameter, mm)                31,88 4,76 32,16 4,62 31,40 5,10 n.s.
Right atrium volume (ml) 34,2 10,2 33,2 7,9 34,8 12,7 n.s.
Septum thickness of LV (mm)              9,33 1,62 9,48 1,83 9,07 1,22 n.s
Posterior wall thickness (mm)   8,78 1,14 8,84 1,21 8,67 1,05 n.s
LV end-diastolic diameter (mm)    43,28 4,65 43,00 4,43 43,73 5,12 n.s
Pulmonary AT (msec) 137,70 28,36 137,7 27,21 137,67 31,16 n.s
TAPSE (mm) 22,80 4,12 22,92 4,37 22,60 3,81 n.s
TAV (cm/s) 13,03 2,13 13,12 2,23 12,88 2,03 n.s
RV end-diastolic area (cm2) 14,2 2,3 14,3 2,1 14,1 2,9 n.s.
RV end-systolic area (cm2) 7,7 2,1 7,4 8,6 7,7 2,1 n.s
RV FS (%) 46,3 8,3 51,2 7,3 46,3 4,9 n.s.
Right atrial pressure (mmHg) 5,25 0,81 5,36 0,95 5,07 0,46 n.s
Resting PAsP (mmHg) 26,48 4,64 25,00 3,85 28,93 4,92 0,0077
Exercise PAsP (mmHg) 45,13 14,17 36,88 8,77 58,87 10,20 0,00
Δ PAsP (mmHg) 18,65 11,91 11,88 7,71 29,93 8,65 0,00
Resting LV ESV (ml/mq) 13,76 3,55 14,05 3,24 13,28 4,09 n.s.
Resting LV EF (%) 67,33 5,82 66,76 5,75 68,27 6,01 n.s
Exercise LV EF (%) 71,00 4,68 70,68 4,33 71,53 5,33 n.s
Resting E/E' ratio 7,37 1,90 7,00 1,66 7,98 2,17 n.s
Exercise E/E' ratio 7,73 2,02 7,54 1,93 8,05 2,20 n.s
Resting VTI s wave PVF 17,14 3,47 16,33 2,89 18,48 4,02 n.s
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Exercise VTI s wave PVF 15,69 3,57 15,32 2,98 16,31 4,43 n.s
Resting VTI d wave PVF 10,98 2,61 11,28 2,67 10,46 2,52 n.s
Exercise VTI d wave PVF 10,56 3,23 10,72 3,39 10,30 3,06 n.s
     AP: antero-posterior; LV: left ventricle; RV: right ventricle; VTI: velocity-time integral; 
      FS: fractional shortening; PVF: pulmonary venous flow.
Among the functional  data,  we observed a  statistically significant  difference in resting
systemic blood pressure (p 0.00318),  and variation of  oxygen saturation  with  exercise
between  the  two  groups  (p  0.0481).  No  other functional  variables  showed  difference
between group A and B (Table 3).  
Table 3. Functional parameters and BNP measurement of the study population, divided
according to the pulmonary vascular response to stress.
Hemodynamics and 
functional parameters
Patients
(N=40)
Subgroup with
normal vascular
reactivity   
(N=25) 
Subgroup with
impaired vascular
reactivity   
(N=15) 
P value
 mean sd mean sd mean sd
Resting systolic BP (mmHg) 117,95 23,71 111,68 20,86 128,40 25,15 0,00318
Exercise systolic BP (mmHg) 165,63 25,15 162,12 27,39 171,47 20,42 n.s.
Resting diastolic BP (mmHg) 75,08 12,43 71,84 11,07 80,46 13,08 n.s.
Exercise diastolic BP (mmHg) 82,93 11,33 81,32 10,20 85,60 12,93 n.s.
Δ systolic BP (mmHg) 47,68 20,99 50,44 17,91 43,07 25,32 n.s.
Δ diastolic BP (mmHg) 7,85 10,44 9,48 11,21 5,13 8,71 n.s.
Resting heart rate (bpm) 75,08 10,09 74,08 9,69 78,67 10,43 n.s.
Exercise heart rate (bpm) 132,58 20,24 131,48 21,39 134,40 18,74 n.s.
Δ  heart rate (bpm) 56,78 22,26 57,40 22,83 55,73 22,01 n.s.
Δ oxygen saturation (%) 1,83 1,77 1,40 1,44 2,53 2,07  0.0481
Maximal heart rate (bpm) 167,78 9,84 170,04 9,02 164,00 10,30 n.s.
% maximal heart rate (%) 79,13% 11,96 77,4 12,47 82,02 10,85 n.s.
Effort duration (min) 7,8 2,5 7,8 2,4 7,3 2,5 n.s.
Resting BNP value (pg/ml) 28,38 27,27 25,27 28,07 33,51 26,05 n.s.
Exercise BNP value (pg/ml) 48,11 40,94 37,72 36,34 64,74 43,58 0,01
Δ BNP value 19,74 19,47 12,55 13,15 31,23 22,7  0,0006
         BP: blood pressure.
Finally  the  BNP  dosage  showed  a  wide  dispersion  of  the  values  with  an  average
concentration of 28.38 ± 27,27 pg/ml at rest, and 48,11 ± 40,94 pg/ml at peak exercise.
Moreover subjects of group B showed higher exercise BNP levels than those of group A
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(64,74 ± 43,58 pg/ml versus 37,72 ± 36,34 pg/ml), with no differences regarding resting
BNP values. Variation of BNP values with exercise (ΔBNP) resulted higher in group B
patients than group A and there was also a  significant linear correlation between ΔBNP
values and  the development of altered pulmonary vascular  responsiveness (figure 1 and
2).
                     Figure 1. Comparison of ∆BNP during exercise between the two patients groups.
                Figure 2. Linear correlation between delta BNP and the development  
                of impaired pulmonary vasoreactivity induced by exercise. r = 0,4171.
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Follow-up
Our patient population were re-evaluated after about five years (5,1  ±  0,4 years); during
this period, 2 patients died for acute leukemia and lung cancer, and 2 patients were lost.
One patient belonged to group A, the other 3 patients (included patients that died) belonged
to group B. So we performed a clinical and echocardiographic assessment in 36 patients.
We  found  that  within  group  B,  5  patients  (41,7%),  all  female  subjects,  had
echocardiographic diagnosis of PAH (group D); according to the latest ESC guidelines, 3
out of these 5 patients had a diagnosis of possible PAH (presenting a tricuspid regurgitant
velocity between 2.9 and 3.4 m/sec, corresponding to a PAsP between 37 and 50 mmHg)
and 2 out of 5 patients  had a diagnosis of probable PAH (with a tricuspid regurgitant
velocity > 3.4 m/sec, corresponding to a PAsP > 50 mmHg). Only one patient underwent
right heart catheterization, that confirmed the diagnosis of pre-capillary PAH; the other
patient refused the test and for the other 3 patients, with a mild increase of the PAsP, and
absence of symptoms, we decided to performed a close clinical and echocardiographic
follow-up. None of the patients of group A presented, at follow-up increased values of
PAsP at rest. At follow-up we newly defined three groups of patients as shown in figure 3
and table 4.
Figure 3.
                                                                    Exercise echocardiography
                                                                                                                                
                                                               Follow-up
                                                                p = 0,003
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  Table 4. distribution of the groups at follow-up, on the basis of PAsP value at rest.
Follow-up 
Normal 
(PAsP <37 mmHg)
Resting PAH
(PAsP >37 mmHg) Total
Baseline
Normal response       
(Exercise PAsP < 48
  mmHg)
24 (100%)
(group E)
0 (0%)
(group F)
24
Impaired response
(Exercise PAsP ≥ 48
   mmHg)
    7 (58,3%)
(group C)
5 (41,7%)
(group D) 12
Total 31 (86,1%) 5 (13,9%) 36
    P=0,003
We made comparison between group C and group D (all belonging to group B, defined as
group with altered pulmonary vascular reactivity at exercise echocardiography), and also
comparison between group D (who developed at follow-up PAH at rest) and the rest of
population (group C and group E), regarding clinical parameters (table 5 and 6).
Table 5. Comparison regarding clincal parameters between group D and the other groups.
Clinical parameters    Patients      Group D Others groups
(C+E) 
P value
Number (%) n= 36 (100%) n=5 (13,9%) n=31 (86,1%)
Males (n, %)        6 (21,6%) 0 (0%)    6 (19,3%) n.s.
Females (n, %) 30 (83,3%)  5 (100%)  25  (80,7%)
Age (years)                         56,7±10,1  68,8± 6,7 54,7±9,2 0,025
Limited sclerosis (n, %)    20 (55,6%) 3 (60%) 17 (54,8%)
n.s.
Diffuse sclerosis (n, %)    16 (44,4%) 2 (40%) 14 (45,2%)
Length of  disease (years)   13,7±5,3 16±6,9 13,5±5,8 n.s. 
Antibody subset:
Scl-70    (n, %)                    
ACA  (n, %)                        
Nonspecific pattern (n, %)
  14 (38,9%)
  16 (44,4%)
   6 (16,7%)
2 (40%)
2 (40%)
1 (20%)
12 (38,7%)
14 (45,2%)
5 (16,1%)
n.s.
Functional class:
NYHA I    (n, %)           
NYHA II  (n, %)
NYHA III (n, %)
25 (69,4%)
9 (25%)
2 (5,6%)
2 (40%)
3 (60%)
0
23 (74,2%)
 6 (19,4%)
2 (6,4%)
n.s.
n.s.
BSA (m2) 1,70±0,2 1,65±0,13 1,7±0,2 n.s.
Pulmonary functional test:
TLCO/VA (%) 69,7±0,2 72,8±32 69,2±17,3 n.s.
FVC (%) 99,1±0,2 96,6±19,1 99,5±18,7 n.s.
Interstitial lung disease
Grade 0 (n, %)
Grade 1 (n, %)
Grade 2 (n, %)
Grade 3 (n, %)
n=34
19 (55,9%)
11 (32,3%)
4 (11,8%)
0
n=4
0
2 (50%)
2 (50%)
0
n=30
19 (63,3%)
9 (30%)
2 (6,7%)
0
n.s.
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Table 6. Comparison regarding clinical parameters between group D and C.
Clinical parameters    Patients        Group D Group C P value
Number (%) n= 12 (100%) n= 5 (41,7%) n= 7 (58,3%)
Females (n, %) 12 (100%) 5 (100%)  7 (100%) -
Age (years)                        60,75±11,1  68,8± 6,7 55± 10,2 0,025
Limited sclerosis (n, %)    8 (66,7%)  3 (60%) 5 (71,4%)
n.s.
Diffuse sclerosis (n, %) 4 (33,3%) 2 (40%) 2 (28,6%)
Length of  disease (years)  13,8±5,87 16±6,9 12,2±4,9 n.s. 
Antibody subset:
Scl-70 (n, %)                      
ACA (n, %)                        
Nonspecific pattern (n, %)
 8 (66,7%)
3 (25%)
1 (8,3%)
2 (40%)
2 (40%)
1 (20%)
 6 (85,7%)
 1 (14,3%)
0 (0%)
n.s.
Functional class:
NYHA I (n, %)           
NYHA II (n, %)
8 (66,7%)
4 (33,3%)
2 (40%)
3 (60%)
6 (85,7%)
1 (14,3%)
 n.s.
BSA (m2) 1,64±0,1 1,65±0,13 1,6±0,8 n.s.
Pulmonary functional test:
TLCO/VA (%) 72,2±22,2 72,8±32 71,7±14,8 n.s.
FVC (%) 100,1±13,6 96,6±19,1 102,6±9,03 n.s.
Interstitial lung disease
Grade 0 (n, %)
Grade 1 (n, %)
Grade 2 (n, %)
Grade 3 (n, %)
n=11
5 (45,4%)
4 (36,4%)
2 (18,2%)
0
n=4
0
2 (50%)
2 (50%)
0
n=7
5 (71,4%)
2 (28,6%)
0
0
n.s.
We observed significant differences only for the age between group D and group C and
also between group D and the rest of population (group C + E), resulting more advanced in
group B than the other groups. The other clinical characteristics didn't show differences.
Regarding pulmonary functional data, patients belonging to group B had a more advanced
grade of interstitial lung disease than group C and the rest of population (group C + group
E). Regarding values of BNP at peak of exercise and the difference between BNP values at
resting  and  at  peak  exercise  (during  evaluation  performed  in  2009)  we  didn't  find
difference between the groups.
                                                                      87
DISCUSSION
Pulmonary arterial hypertension is one of the leading causes of death in patients with SSc.
The growing availability of new efficacious therapies gives a pivotal role to the research of
tools able to early identify patients at higher risk for developing this severe complication.
Early diagnosis could be the better  way to improve the survival. The reduced vascular
reserve in response to stress is an important feature of the pulmonary arterial hypertension
and, for this mechanism, the exercise, in such patients, induces a marked increase of the
PAsP values.  Conversely  the  normal  pulmonary  circulation  is  unique  in  its  ability  to
accomodate the entire  cardiac output  at  low arterial  pressure even during condition of
maximal exercise. This is accomplished by its high-capacitance and low-resistance circuit,
with large microcirculatory reserve which are 'unrecruited'  at  rest.  During exercise,  the
pulmonary  microcirculation  is  progressively  recruited,  resulting  in  the  maintenance  of
relatively  low  arterial  pressure  despite  increasing  flow.  The  recruitment  of  the
microcirculation  also  serves  to  increase  the  capillary  surface  area  available  for  gas
exchange during exercise. The high capacitance of the pulmonary circulation means that
early pulmonary vascular  disease  can  be well  compensated for.  In  fact,  > 50% of  the
pulmonary circulation must be obstructed before a rise in resting PAP is detected. Thus a
rise in resting PAP is a late marker of the obliterative and remodeling processes occurring
in  the  distal  pulmonary  arteries  [126].  Exercise  coul  be  a  useful  'stress'  to  elicit  an
abnormal  response  to  facilitate  disease  detection,  and  for  this  reason  exercise
echocardiography could be a diagnostic tool to early identify pulmonary vascular disease
when resting hemodynamics do not permit to detect the initial phase of the disease [16]. In
systemic  sclerosis  abnormalities  of  the  pulmonary  physiology  recognize  the  primum
movens as the endothelial dysfunction of the arterioles and capillaries leading to platetel
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aggregation, muscular layer proliferation, thickening of the tunica intima and adventitia,
and  lastly  reduced  vascular  compliance  and  vessel  occlusion.  These  processes  lead  to
reduction of pulmonary vessel bed that exhibits a rise in pulmonary arterial pressure during
efforts, and absence of symptom and normal pulmonary arterial pressure at rest.
Pulmonary vascular involvement is present in two-thirds of patients with SSc [127], but
this  initial  phase  of  the  disease  is  clinically  silent  and  detectable  pathophysiological
changes in  the pulmonary circulation usually appear  when the pathological  lesions are
fully developed. The length of this pre-clinical phase of the disease is currently unknown
[128], but if we consider that late symptoms reporting and delayed diagnosis are common
in PAH, it is clear how distant the early stage of the disease may be from the initiation of
effective therapies. Therefore it is mandatory to reduce the time between the beginning of
the  pathobiological  processes  leading  to  PAH  and  the  initiation  of  effective  medical
therapy. The first studies made in the nineties, considered small groups of patients, affected
by LES or SSc, that showed a significative increase of the pulmonary pressure respect to
healthy subjects [129,130]. From 2001 departments of Rheumatology, Pneumology and
Cardiology  of  the  University  of  Connecticut  became  to  perform  annual  stress
echocardiographic  studies  in  patients  with  SSc,  starting  with  such  experimental  tool.
Therafter the studies conducted by Steen [61], Tolle [16], Alkobot [131], Collins [96] and
D'Alto [101], confirmed the high prevalence of altered pulmonary vasoreactivity induced
by exercise in SSc patients, although the cut-off values for its definition are rather not
well-defined.  More  recently  study  groups  of  Pavia  and  Naples  made  a  follow-up  of
patients with pulmonary altered vasoreactivity induced by exercise revealing in this group
a worse prognosis than patients without pulmonary altered vasoreactivity [102]. 
Our study was conducted only with asymptomatic or midly symptomatic patients, that are
not considered at high risk for PAH development (as patients with clear symptoms, altered
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pulmonary functional  tests  or  with  echocardiographic  findings),  but  they need  a  close
clinical follow-up because represent the majority of patients affected by SSc, and in whom
diagnosis of PAH is always made very late.   
Exercise  echocardiography was  able  to  identify  two  SSc  patients  groups  presenting  a
different  vascular  response to  exercise.  Assimunig a  PAsP cut-off  value of  48 mmHg,
37,5% of our patients showed an altered pulmonary vasoreactivity induced by exercise,
that  is  more  or  less  the prevalence  as  already described in  literature in  various  works
[61,97-99,131,132]. Actually prevalence of PAH in SSc is much lesser (from 7% to 12%)
than the prevalence of altered pulmonary vasoreacitvity and the reason of this difference is
that the reduced pulmonary vessels  compliance and vasodilation response is  a peculiar
feature of SSc patients. Subjects with exercise pulmonary abnormal vasoreactivity (group
B) had both higher resting and exercise PAsP values that the other group, as also confirmed
in other studies [101]. Also the change between resting and exercise PAsP (delta, ΔPAsP)
was found higher in group B than group A; such parameter in a study was also assumed as
the index to define altered pulmonary vasoreactivity induced by exercise, instead of the
absolute  value  of  PAsP reached  during  exercise  [61].  Regarding  the  analysis  of  the
functional capacity of SSc patients, group B patients performed less effort than the other
group regarding both the duration of the exercise and the submaximal heart rate reached,
but the data were not statistically significant. We did not observe a correlation between the
exercise PAsP values and the duration of the effort, in agreement to Alkotob et al [131]. In
SSc the  presence  of  reduced functional  capacity  caused by various  physiopathological
mechanisms,  other  than  the  presence  of  PAH:  pleuropulmonary  alterations,  muscular
inflammations, arthiritis, steroidal drugs use, deconditioning, but especially the presence of
interstitial lung disease and pulmonary fibrosis [16].
Patients of our study had normal systo-diastolic echocardiographic parameters, that were
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also confirmed during exercise echocardiography. In particular the estimate of diastolic
filling pressures resulted normal during exercise, assuming that the increase of PAsP could
have a  precapillary origin rather than due to diastolic dysfunction. Recently D'Alto et al.
found that  diastolic  dysfunction  and the  presence  of  interstitial  lung disease can often
explain  the  increase  in  PAsP during  exercise  echocardiography,  rather  than  a  primary
pulmonary vascular obstructive disease [101]. Another important datum is represented by
the difference between group A and B regarding the change in oxygen saturation during
exercise (Delta O2 saturation). Oxygen saturation depends on the respiratory gas exchange
diffusion capacity, so alterations of the capillary vessels walls, even in the initial phase of
the  disease,  limit  the  oxygen  and  carbon  dioxide  passage  across  the  alveolo-capillary
membrane, causing a slight desaturation after the effort [133].
BNP measurement  showed no significant difference between the two group (A and B)
regarding resting values, but values at peak exercise and the change between resting and
exercise values (DeltaBNP) are higher in group B than group A. So we found a correlation
between  the  deltaBNP value  and  the  develpment  of  altered  pulmonary  vasoreactivity
induced  by  exercise.  There  are  not  available  studies  evaluating  BNP  values  during
exercise, in this kind of patients. Studies of patients affected by ischemic heart disease,
cardiomyopathies  and  valvular  heart  disease  have  evaluated  BNP values  during  stress
echocardiography. It is also important to point out that the physical activity could per se
increase BNP or NT-proBNP levels in healthy athletes, especially the endurance exercise,
but also in non-atheletes subjects [134]. Our study demonstrated that patients at higher risk
for development of PAH, had higher BNP levels during exercise; this phenomenon could
be explained with the higher pressure overload conditions and wall stretching of the right
ventricle in the group of patients with altered pulmonary vasoreactivity. In conclusion we
can affirm that variations of BNP values with the exercise could represent a biomarker of
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pulmonary  vascular  involvement  in  SSc  patients  and,  together  with  exercise
echocardiography, could help in diagnosing the altered pulmonary vasoreactivity. Baseline
measurement of BNP values did  not show any usefulness in early diagnosis of PAH. 
Our follow-up could be defined a medium- to long-term evaluation. We found that a high
percentage of patients with altered pulmonary vasoreactivity at exercise echocardiography,
developed, after about 5 years PAH (41,7%). These datum is different from that reported
by Codullo et al. revealing a 3,5% of patients developing PAH, in a shorter follow-up (3,5
± 0,2 years) [102]. Condliffe et al. showed in their study that 19% of SSc patients with
exercise PAH diagnosed by right heart catheterization developed resting PAH after a 2,3
years follow-up [73]. Alkotob et al. after a 2 years follow-up didn't show development of
resting PAH in patients perviously submitted to exercise echocardiography who developed
altered pulmonary vasoreactivity. However it is to underline that the cut-off value of PAsP
to define exercise PAH in this study was considered 40 mmHg (a very low value) and was
measured at the end of the exercise, not at peak exercise [131]. 
Data in literature about follow-up of this kind of patients are certainly lacking, because
there are very few studies, with small patient population and with short-term evaluation.
Other interesting data in our follow-up regard the significant difference in terms of the age
between the 5 patients who developed resting PAH and the rest of the population; the first
group resulted older than the other. This could be explained by the fact that PAH, as a
complication of SSc, is more frequent in patients with advanced age, so much that some
authors consider the age a risk factor for developing PAH [135]. Finally our 5 patients with
resting PAH at follow-up showed a more advanced stage of interstitial lung disease than
the other patients, so it is not possible to exclude a role of the lung disease in favoring the
development of altered pulmonary vasoreactivity and ultimately resting PAH. 
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STUDY LIMITATIONS 
Our study lacks a patient control group and is a single-center study with a limited number
of patients enrolled. The right heart catheterization would have certainly provided more
accurate informations about the pulmonary artery and right atrial pressures, but it would
have been difficult to perform such an invasive measurement at baseline evaluation and
during stress test to reach reliable data. In the current guidelines of the European Society of
Cardiology  the  exercise  echocardiography  is  not  recommendend  (class  III,  level  of
evidence C) in patients with suspected PAH [7]. The causes are: the value of a normal
PAsP achieved  during  the  exercise  is  not  well  established,  the  technical  difficulty  to
perform  the  exam,  the  lack  of  a  sufficient  number  of  prospective  studies.  The  main
limitations of this kind of study lie in the limits of the echocardiography itself (the image
quality,  the  difficulty of tricuspid  regurgitation  jet  detection).  In  our  study,
echocardiographic investigations were performed by a single operator and the technology
applied has allowed a limited variability and the ability to measure the pulmonary pressure
in 100% of the cases. Another limitation in our study concerns the parameters of the right
ventricular function (TAPSE and TAV) that were assessed only at rest, as well as the right
atrial pressure,  derived by measuring the size and respiratory excursions of the inferior
vena cava at rest and assumed as a constant value during all the phases of the effort.
At follow-up the study limitations consisted in performinng right heart catheterization in
only one of the 5 patients who developed echocardiographic signs suggestive of PAH. In
this patients RHC confirmed the diagnosis of PAH. 
                                                                      94
                                                                      95
CONCLUSIONS
Exercise echocardiography is a noninvasive, low cost and low risks tecnique that could be
a useful screening tool for early identify a subclinical stage of PAH in a selected patient
population such as SSc patients. 
Early detection of PAH is an important strategic objective in such kind of disease carrying
a very poor prognosis. The future paradigm of early disease detection in high-risk patients
should ideally be aimed at detecting disease prior to a rise in resting PAP.
Exercise  echocardiography uses  a  physiological  'stress'  that  is  the  effort,  to  study the
hemodynamic  response  of  the  pulmonary  circulation  to  detect  the  altered  pulmonary
vasoreactivity  induced  by  exercise.  It  is  hypothesized  that  such  atypical  response  to
exercise is a sign of early PAH disease.
Following  this  kind  of  patients  could  provide  an  early  diagnosis  of  pulmonary
hypertension to early start an effective treatment, improving the prognosis. 
BNP measurement during exercise could also support the diagnosis of altered pulmonary
vasoreactivity made by exercise echocardiography. 
Finally the medium- to long-term follow-up of our patients showed that subjects with an
abnormal  vasoreactivity  response  to  exercise  will  progress  to  resting  PAH  over  time,
validating the predictive value of this method to early identify the disease. 
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SUMMARY OF SCIENTIFIC ACTIVITIES 
DURING PhD COURSE
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PhD course  (2010-2014)
I YEAR (2010/2011)
-  Attendance  to  the  following lessons,  congresses  and scientific  activities  expected
from the  didactic programme of the first year of PhD course:
1.  Seminary  “Anatomy for  electrophysiologist:  conductive  tissue  and  cardiac  pacing”.
Veneto AIAC Regional course. Padua, 18 February 2011.
2. Seminary “Update on myocarditis”. Padua, 11 March 2011.
3. XXX Update course of Pediatric Cardiology. Padua, 19-20 April 2011.
4. Update course “The adult with congenital heart disease”. Padua, 13 May 2011.
5. Simposium “Arrhythmogenic cardiomyopathy: from genes to therapy”. Padua, 20-21
May 2011.
6.  Monday  Meeting  called  “Clinical-pathological  conferences”.  Padua,  Division  of
Anatomy Pathology.
7.  Course “The anatomic basis  of transcatheter  implantation of  prosthetic  aortic  valve.
Padua, 21 October 2011.
8. “Morgagnane Lectures” on Wednesday.
9. “Summer School” Week on Basic Sciences. Padua, 26-30 September 2011.
10. I congress of Pediatric Arrhythmias. Abano Terme, 17-18 November 2011.
Active attendance to congresses (as speaker):
1.  Abstract  presentation  (in  oral  session)  at  European  Congress  of  Echocardiography
(EuroEcho) held in Copenaghen (Denmark), 8-11 December 2010.
Title of the Abstract:  Exercise non-invasive evaluation of the hemodynamic parameters
and brain natriuretic peptide in the setting of pulmonary arterial hypertension in patients
with  scleroderma.  Authors:  V.  Scarabeo, M.G.  Leone,  F  De  Conti,  V.  Degani,  F.
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D’Ambrosio, P Piovesana.
2.  Abstract  presentation  (in  poster  session)  at  National  Congress  of  Italian  Society of
Echocardiography (SIEC) held in Naples , 14-16 April 2011.
Title of abstract: Studio dell’ipertensione polmonare nei pazienti sclerodermici mediante
l’ecocardiogramma da sforzo: valutazione delle variabili emodinamiche e del dosaggio del
BNP.  Authors:  V.  Scarabeo,  M.G.  Leone,  F  De  Conti,  V.  Degani,  F.  D’Ambrosio,  P
Piovesana. 
Teaching activity:
-  Teaching  commitment  for  training  courses  on  Basic  Echocardiography and  Pediatric
Echocardiography organized by the Italian Society of Echocardiography (SIEC).
- Teaching commitment for the following theorical and practical courses for Cardiologists
(with  ECM  accreditation)  held  in  the  Department  of  Cardiology  of  Camposampiero
hospital:
1. Pediatric Cardiology Course (15-16 November 2010).
2. Pediatric Cardiology Course (18-19 April 2011).
3. Mitral valve disease: update on diagnostic and therapeutic approaches (6 May 2011).
4. Course "Thromboembolic risk and atrial fibrillation: the echocardiographic diagnostic 
tool and new therapies on anticoagulant drugs"(8 April 2011).
5. Inflammatory heart diseases (24 June 2011).
                                                                      111
II YEAR (2011/1012)
-  Attendance  to  the  following lessons,  congresses  and scientific  activities  expected
from the  didactic programme of the second year of PhD course:
-  “Challenges” in aortic valvulopathy.  SIC Meeting of Triveneto.  Padua,  26 November
2011.
- Anatomy for the electrophysiologist: ablation of the AV junction and Brugada syndrome.
Regional Course of Veneto AIAC. Padua, 10 February 2012.
- Advances in Medicine. Scientific Symposium. Padua, 23-24 March 2012.
- XXXI Update course in Pediatric Cardiology. Padua, 3-4 April 2012. 
-  Monday  Meeting  called  “Clinical-pathological  conferences”.  Padua,  Division  of
Anatomy Pathology.
- “Morgagnane Lectures” on Wednesday. Padua, Division of Anatomy Pathology.
Forum of Electophysiology. Clinical-pathological Conference. Padua, 25 May 2012.
Teaching activity:
-  Teaching  commitment  for  training  courses  on  Basic  Echocardiography and  Pediatric
Echocardiography organized by the Italian Society of Echocardiography (SIEC).
- Teaching commitment for the following theorical and practical courses for Cardiologists
(with  ECM  accreditation)  held  in  the  Department  of  Cardiology  of  Camposampiero
hospital:
1.  Course  “Therapies  for  Acute  Coronary  Syndrome  and  future  developments  for
prosthetic cardiac valves” (7 December 2011).
2. Pediatric Cardiology Course (10-11 May 2012).
3. Echocardiography in heart failure (20 April 2012).
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4. Thromboembolic risk in atrial fibrillation: new developments on oral anticoagulant 
therapy in preventing ischemic stroke and echocardiographic imaging techniques" (30 
March 2012).
5. Aortic valve stenosis and arterial hypertension (15 June 2012).
6. Diagnostic and therapeutic approaches in bioprosthetic cardiac valves (22 June 2012).
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III YEAR (2012-2013)
Attendance to the following lessons, congresses and scientific activities expected from
the didactic programme of the third year of PhD course:
-  Monday  Meeting  called  “Clinical-pathological  conferences”.  Padua,  Division  of
Anatomy Pathology.
-  Congess  “Anatomy for  the  electrophysiologist:  atrial  fibrillation”.  Padua  2  February
2013.
 - Update Course “Pediatric Cardiology, XXXII Course”. Padua, 27-28 March 2013.
 - Spring School. Bressanone, 12-13 April 2013.
 - Biannual Course “The adult patient with congenital heart disease”. Padua, 17 May 2013.
 - Meeting “Heart transplantation”. Padua, 7 June 2013.
Teaching activity:
-  Teaching  commitment  for  training  courses  on  Basic  Echocardiography and  Pediatric
Echocardiography organized by the Italian Society of Echocardiography (SIEC).
- Teaching commitment for the following theorical and practical courses for Cardiologists
(with  ECM  accreditation)  held  in  the  Department  of  Cardiology  of  Camposampiero
hospital:
1.  Heart  failure  and  hypertensive  heart  disease:  integration  between echocardiographic
imaging tecnique and biohumoral parameters (19 April 2013). 
2. Thromboembolic risk in atrial fibrillation: new developments on oral anticoagulant 
therapy in preventing ischemic stroke and echocardiographic imaging techniques" (3 May 
2013).
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IV YEAR (2013-2014)
Attendance to the following lessons, congresses and scientific activities expected from
the didactic programme of the fourth year of PhD course:
-  Monday  Meeting  called  “Clinical-pathological  conferences”.  Padua,  Division  of
Anatomy Pathology.
-  Congress  “Anatomy for  the  electrophysiologist:  the  arrhythmic  risk  in  mitral  valve
prolapse". Padua 1 February 2014.
-  International  Symposium  “Update  in  Arrhythmogenic  cardiomyopathy  and  sudden
cardiac  death  in  the  young:  novel  technologies  in  cardiology,  genetics  and  pathology.
Padua, 20-21 March 2014.
- XXXIII Update Course in Pediatric Cardiology: sudden infant death syndrome, complete
transposition of the great vessels. Padua, 16-17 April 2014. 
- Spring School-Bressanone, 31 May-1 June 2014. 
- Forum of Electrophysiology “Monitoring of arrythmias: present and future”. Padua, 6
June 2014.
Teaching activity:
-  Teaching  commitment  for  training  courses  on  Basic  Echocardiography and  Pediatric
Echocardiography organized by the Italian Society of Echocardiography (SIEC).
- Teaching commitment for the following theorical and practical courses for Cardiologists
(with  ECM  accreditation)  held  in  the  Department  of  Cardiology  of  Camposampiero
hospital:
1. Hypertensive heart disease and aortic valve stenosis: echocardiographic approach and
new surgical perspectives (23 May 2014).
2. Thromboembolic risk in atrial fibrillation: new developments on oral anticoagulant 
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therapy and echocardiographic imaging techniques" (9 May 2014).
3. Heart failure and hypertensive heart disease (3 October 2014).
Published scientific works:
- Migliore F, Scarabeo V, Corfini A, Piovesana P. Microbubbles contrast inside the cyst: a
pathognomonic sign of mitral valve blood cyst. J Cardiovasc Med 2010; 11(4):294-296.
Abstracts
- V. Scarabeo, M.G. Leone, F De Conti, V. Degani, F. D’Ambrosio, P Piovesana. Exercise
non-invasive evaluation of the hemodynamic parameters and brain natriuretic peptide in
the  setting  of  pulmonary  arterial  hypertension  in  patients  with  scleroderma.  European
Journal of Echocardiography 2010; 11, Suppl 2 (Abstr): 653.
- V. Scarabeo, M.G. Leone, F De Conti, V. Degani, F. D’Ambrosio, P Piovesana. Studio
dell’ipertensione  polmonare  nei  pazienti  sclerodermici  mediante  l’ecocardiogramma da
sforzo: valutazione delle variabili emodinamiche e del dosaggio del BNP. Abstract. XV
Congresso Nazionale della  Società  italiana di Ecografia  cardiovascolare.  Napoli,  14-16
Aprile 2011.
-  P.Turrini,  M.S.  Baccillieri,  V.  Scarabeo,  F.  De  Conti,  A.  Stendardo,  R.  Verlato.
Incremento improvviso della soglia ventricolare destra e dell’impedenza di shock cavale in
paziente portatore di Sprint Fidelis  seguito con CareLink; una causa inattesa.  Giornale
Italiano di Aritmologia e Cardiostimolazione 2012; 15, Suppl 1 (Abstr): 98.
- M.S. Baccillieri, M Busa, P.Turrini, A. Gloria, A. Berton, A. Di Marco, F. De Conti, V.
Scarabeo,  A.  Stendardo,  R.  Verlato.  Inefficacia  del  dronedarone  prescritto  secondo  le
indicazioni  dell’AIFA per  prevenire  la  fibrillazione  atriale  in  soggetti  con  precedente
sospensione  di  amiodarone  per  qualunque  ragione.  Giornale  Italiano  di  Aritmologia  e
Cardiostimolazione 2012; 15, Suppl 1 (Abstr): 12
- P. Turrini, M.S. Baccillieri,  F.  Campisi,   A. Di Marco, F. De Conti,  A. Stendardo, V.
Scarabeo,  M. Busa, A. Gloria, A. Berton, G. Gerosa, R. Verlato. Effetto sinergico della
CRT  con  VAD  Jarvik:  descrizione  di  un  caso.  Giornale  Italiano  di  Aritmologia  e
Cardiostimolazione 2012; 15, Suppl 1 (Abstr): 129.
- M. Busa, V.Scarabeo, M. Noni, A. Berton, M. Mion, P. Piovesana. Cardiotossicità da
Antracicline:  ruolo  dell’ecocardiografia  parametrica  nell’identificazione  del  danno
precoce. Giornale Italiano di Cardiologia 2012; 13, Suppl 2 (Abstr): 164.
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- P. Piovesana, P. Offelli, F. D’Ambrosio, F. De Conti, V. Scarabeo, M. Panfili, F. Antonini-
Canterin.  A new Stress  Echo  protocol  to  increase  sensitività:  dipyridamole  follone  by
exercise. Giornale Italiano di Cardiologia 2012; 13, Suppl 2 (Abstr): 499.
- A. Berton, V. Scarabeo, M. Busa, M. Rizzo, F. Cozzi, P Piovesana. Valore predittivo della
valutazione non invasiva dei parametri emodinamici e del BNP durante ecocardiografia da
sforzo nell’identificazione precoce dell’ipertensione polmonare nei pazienti sclerodermici;
follow-up a due anni. Giornale Italiano di Cardiologia 2012; 13, Suppl 2 (Abstr): 533.
- M. Beraldo, M. Panfili, F. De Conti, V. Scarabeo, P Piovesana. Ecostress dipiridamolo pù
sforzo: quale significato assume un risultato negativo? Giornale Italiano di Cardiologia
2013; Vol. 14, Suppl 1 (Abstr): P 451.
- M. Beraldo,  M. Panfili, F. De Conti, V. Scarabeo, P Piovesana. Valore diagnostico di una
nuova metodologia di induzione di ischemia utilizzando l’associazione di dipiridamolo e
sforzo fisico. Giornale Italiano di Cardiologia 2013; Vol. 14, Suppl 1 (Abstr) : P452.
-  M.  Busa,  M.  Nonj,  V.  Scarabeo,  A.  Berton,  M.  Mion,  P.  Piovesana.  Ruolo
dell’ecocardiografia parametrica nella definizione precoce della tossicità da antraci cline.
Giornale Italiano di Cardiologia 2013; Vol. 14, Suppl 1 (Abstr) : C80.
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Curriculum Vitae
PERSONAL
INFORMATION Virginia Scarabeo 
Via Euganea 43, 35141 Padova (Italy) 
 + 39 347 4724272    
 virginia.scarabeo@libero.it 
POSITION Medical doctor
WORK EXPERIENCE  
01/03/2005–Present Full-time employment with open-ended contract as medical doctor 
cardiologist at Department of Cardiology of Camposampiero Hospital 
(ULSS 15 Alta Padovana, Veneto)
Camposampiero (Italy) 
Medical activities in Cardiology ward, Intensive Coronary Care Unit, Ambulatory 
Division and Laboratory of Echocardiography.
22/03/2004–
28/02/2005
Full-time employment with open-ended contract, as medical doctor 
cardiologist at Department of Cardiology of Portogruaro Hospital (ULSS 
10 "Veneto Orientale")
Portogruaro (Italy) 
07/04/2003–
21/03/2004
Full-time employment with fixed-term contract as medical doctor 
cardiologist at Department of Cardiology of Pieve di Cadore hospital 
(ULSS n.1, Belluno)
Pieve di Cadore (Italy) 
EDUCATION AND
TRAINING  
2010–Present Doctoral (PhD) course in Clinical and Experimental 
Sciences. Curriculum: Cardiovascular Sciences.
University of Padua, Padova (Italy) 
01/01/2010–16/12/2010 Second-level short specialisation degree in 
Cardiovascular Pathology
University of Padua, Padova (Italy) 
01/01/2008–19/01/2009 Second-level short specialisation degree in Pediatrics 
and its sub-specialty areas: Cardiology.
University of Padua, Padova (Italy) 
01/01/1998–16/12/2002 School Specialisation degree in Cardiology
University of Padua (II School of Cardiology), Padova (Italy) 
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-10/1992–20/10/1998 Academic degree in Medicine and Surgery
Catholic University of the Sacred Heart in Rome, Roma (Italy) 
1987–07/1992 Secondary School Diploma in Classical Studies
Liceo-Ginnasio "A. Giordano", Venafro (IS) (Italy) 
PERSONAL SKILLS  
Mother tongue(s) Italian
Other language(s) UNDERSTANDING SPEAKING WRITING
Listening Reading Spoken interaction Spoken production
English B2 B2 B1 B2 B2
Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user
Common European Framework of Reference for Languages 
Computer skills Knowledge and application of Microsoft Office programmes
Driving licence A, B
ADDITIONAL
INFORMATION  
From 2012 teaching activity in Basic and Pediatric Echocardiography Courses 
organized by the Italian Society of Echocardiography (SIEC). 
From 2011 teaching activity in theoretical-practical courses for cardiologists held in the 
Department of Cardiology of Camposampiero hospital.
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Publications and abstracts
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